EP4258874A1 - Antiviral olive extract compositions and methods - Google Patents
Antiviral olive extract compositions and methodsInfo
- Publication number
- EP4258874A1 EP4258874A1 EP21904253.8A EP21904253A EP4258874A1 EP 4258874 A1 EP4258874 A1 EP 4258874A1 EP 21904253 A EP21904253 A EP 21904253A EP 4258874 A1 EP4258874 A1 EP 4258874A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- hidrox
- cov
- sars
- olive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 183
- 240000007817 Olea europaea Species 0.000 title claims abstract description 53
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims description 53
- 239000000284 extract Substances 0.000 title description 11
- 208000036142 Viral infection Diseases 0.000 claims abstract description 17
- 230000009385 viral infection Effects 0.000 claims abstract description 17
- 208000024891 symptom Diseases 0.000 claims abstract description 12
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims description 226
- 241001678559 COVID-19 virus Species 0.000 claims description 112
- 235000003248 hydroxytyrosol Nutrition 0.000 claims description 110
- 229940095066 hydroxytyrosol Drugs 0.000 claims description 110
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 90
- -1 pinoresinol lignan Chemical class 0.000 claims description 66
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 claims description 60
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 50
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 claims description 46
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 35
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 34
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 34
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 29
- FIKLMMHLPVXWJN-WRWORJQWSA-N Elenolic acid Chemical compound COC(=O)C1=CO[C@@H](O)C(=CC)[C@@H]1CC(O)=O FIKLMMHLPVXWJN-WRWORJQWSA-N 0.000 claims description 27
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 24
- 235000004330 tyrosol Nutrition 0.000 claims description 24
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 claims description 23
- 229930003935 flavonoid Natural products 0.000 claims description 23
- 235000017173 flavonoids Nutrition 0.000 claims description 23
- 235000009408 lignans Nutrition 0.000 claims description 23
- 150000002989 phenols Chemical class 0.000 claims description 23
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 claims description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 claims description 22
- DEBZOPZQKONWTK-UHFFFAOYSA-N aldehydic form of oleuropein aglycone Natural products COC(=O)C1=COC(C)C(C=O)C1CC(=O)OCCC1=CC=C(O)C(O)=C1 DEBZOPZQKONWTK-UHFFFAOYSA-N 0.000 claims description 22
- 235000011576 oleuropein Nutrition 0.000 claims description 22
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 claims description 22
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 claims description 22
- 235000007221 pinoresinol Nutrition 0.000 claims description 22
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 claims description 22
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 22
- 229940074391 gallic acid Drugs 0.000 claims description 21
- 235000004515 gallic acid Nutrition 0.000 claims description 21
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 claims description 20
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 claims description 20
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 17
- 229940074360 caffeic acid Drugs 0.000 claims description 17
- 235000004883 caffeic acid Nutrition 0.000 claims description 17
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 17
- 229960005219 gentisic acid Drugs 0.000 claims description 17
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 16
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims description 16
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 16
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 16
- 235000005493 rutin Nutrition 0.000 claims description 16
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 16
- 229960004555 rutoside Drugs 0.000 claims description 16
- 150000002215 flavonoids Chemical class 0.000 claims description 12
- 229930013686 lignan Natural products 0.000 claims description 12
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 claims description 11
- GMQXOLRKJQWPNB-UHFFFAOYSA-N (8E)-ligstroside Natural products CC=C1C(CC(=O)OCCC=2C=CC(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O GMQXOLRKJQWPNB-UHFFFAOYSA-N 0.000 claims description 11
- JCWFMPVGIIRRRG-XJOAVPHSSA-N 10-Hydroxyoleuropein Natural products O=C(OCCc1cc(O)c(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC JCWFMPVGIIRRRG-XJOAVPHSSA-N 0.000 claims description 11
- AHTRGGWSBFOEEG-JSTGBQKGSA-N 10-hydroxyligstroside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CCO)[C@@H]1CC(=O)OCCc3ccc(O)cc3 AHTRGGWSBFOEEG-JSTGBQKGSA-N 0.000 claims description 11
- JCWFMPVGIIRRRG-UHFFFAOYSA-N 10-hydroxyoleuropem Natural products OCC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O JCWFMPVGIIRRRG-UHFFFAOYSA-N 0.000 claims description 11
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 11
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 11
- GMQXOLRKJQWPNB-JSTGBQKGSA-N Ligstroside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OCCc3ccc(O)cc3 GMQXOLRKJQWPNB-JSTGBQKGSA-N 0.000 claims description 11
- XLPXUPOZUYGVPD-XNJYKOPJSA-N Oleacein Chemical compound C\C=C(/C=O)C(CC=O)CC(=O)OCCC1=CC=C(O)C(O)=C1 XLPXUPOZUYGVPD-XNJYKOPJSA-N 0.000 claims description 11
- 229940087168 alpha tocopherol Drugs 0.000 claims description 11
- QWEKFUBDXQTUTJ-LRPGRGPISA-N demethyloleuropein Chemical compound O([C@H]1C([C@@H](C(=CO1)C(O)=O)CC(=O)OC=CC=1C=C(O)C(O)=CC=1)=CC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWEKFUBDXQTUTJ-LRPGRGPISA-N 0.000 claims description 11
- XLPXUPOZUYGVPD-UHFFFAOYSA-N dialdehydic form of decarboxymethyl oleuropein aglycone Natural products CC=C(C=O)C(CC=O)CC(=O)OCCC1=CC=C(O)C(O)=C1 XLPXUPOZUYGVPD-UHFFFAOYSA-N 0.000 claims description 11
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 11
- GMQXOLRKJQWPNB-MVVLSVRYSA-N ligstroside Chemical compound O([C@@H]\1OC=C([C@H](C/1=C\C)CC(=O)OCCC=1C=CC(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMQXOLRKJQWPNB-MVVLSVRYSA-N 0.000 claims description 11
- JCWFMPVGIIRRRG-AXPMACIOSA-N methyl (4s,5e,6s)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-(2-hydroxyethylidene)-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate Chemical compound O([C@@H]\1OC=C([C@H](C/1=C\CO)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JCWFMPVGIIRRRG-AXPMACIOSA-N 0.000 claims description 11
- DEBZOPZQKONWTK-KWCYVHTRSA-N oleuropein aglycone Natural products COC(=O)C1=CO[C@H](C)[C@@H](C=O)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 DEBZOPZQKONWTK-KWCYVHTRSA-N 0.000 claims description 11
- BIWKXNFEOZXNLX-BBHIFXBUSA-N oleuropein aglycone Chemical compound COC(=O)C1=CO[C@@H](O)\C(=C\C)[C@@H]1CC(=O)OCCC1=CC=C(O)C(O)=C1 BIWKXNFEOZXNLX-BBHIFXBUSA-N 0.000 claims description 11
- 229960000984 tocofersolan Drugs 0.000 claims description 11
- 235000011557 tyrosol esters Nutrition 0.000 claims description 11
- KDSWDGKIENPKLB-QJDQKFITSA-N verbascoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)CCC=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O KDSWDGKIENPKLB-QJDQKFITSA-N 0.000 claims description 11
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims description 11
- 239000002076 α-tocopherol Substances 0.000 claims description 11
- 235000004835 α-tocopherol Nutrition 0.000 claims description 11
- 229920006389 polyphenyl polymer Polymers 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 229940120503 dihydroxyacetone Drugs 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 8
- 235000019260 propionic acid Nutrition 0.000 claims description 8
- DFGRBDTXILTPTO-UHFFFAOYSA-N 2,2,3-trihydroxybutanoic acid Chemical compound CC(O)C(O)(O)C(O)=O DFGRBDTXILTPTO-UHFFFAOYSA-N 0.000 claims description 5
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 5
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 5
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- AVVWPBAENSWJCB-RSVSWTKNSA-N D-galactofuranose Chemical compound OC[C@@H](O)[C@@H]1OC(O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-RSVSWTKNSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- QXKAIJAYHKCRRA-UHFFFAOYSA-N D-lyxonic acid Natural products OCC(O)C(O)C(O)C(O)=O QXKAIJAYHKCRRA-UHFFFAOYSA-N 0.000 claims description 4
- QXKAIJAYHKCRRA-FLRLBIABSA-N D-xylonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-FLRLBIABSA-N 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N keto-D-fructose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 72
- 210000004027 cell Anatomy 0.000 description 54
- 230000003612 virological effect Effects 0.000 description 50
- 230000003253 viricidal effect Effects 0.000 description 46
- 238000002474 experimental method Methods 0.000 description 37
- 230000037396 body weight Effects 0.000 description 30
- 238000009472 formulation Methods 0.000 description 28
- 102100031673 Corneodesmosin Human genes 0.000 description 26
- 101710139375 Corneodesmosin Proteins 0.000 description 26
- 229960004106 citric acid Drugs 0.000 description 26
- 230000035755 proliferation Effects 0.000 description 23
- 230000035484 reaction time Effects 0.000 description 23
- 238000011534 incubation Methods 0.000 description 22
- 239000006071 cream Substances 0.000 description 18
- 238000001514 detection method Methods 0.000 description 16
- 238000001262 western blot Methods 0.000 description 16
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 15
- 239000003085 diluting agent Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000001629 suppression Effects 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 12
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 235000013824 polyphenols Nutrition 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 241000315672 SARS coronavirus Species 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 239000012085 test solution Substances 0.000 description 11
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 10
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 10
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000002378 acidificating effect Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 101710141454 Nucleoprotein Proteins 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 7
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 7
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 7
- 239000004909 Moisturizer Substances 0.000 description 7
- 239000005642 Oleic acid Substances 0.000 description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 7
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 7
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 7
- 235000009498 luteolin Nutrition 0.000 description 7
- 229960004999 lycopene Drugs 0.000 description 7
- 235000012661 lycopene Nutrition 0.000 description 7
- 239000001751 lycopene Substances 0.000 description 7
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 7
- 230000001333 moisturizer Effects 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
- 235000021313 oleic acid Nutrition 0.000 description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 6
- 241000207836 Olea <angiosperm> Species 0.000 description 6
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 6
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 230000001524 infective effect Effects 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000004006 olive oil Substances 0.000 description 6
- 235000008390 olive oil Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- QYIXCDOBOSTCEI-BPAAZKTESA-N (8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1CC2CC(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QYIXCDOBOSTCEI-BPAAZKTESA-N 0.000 description 5
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 5
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 5
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 5
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 5
- 229920002079 Ellagic acid Polymers 0.000 description 5
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 5
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 5
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 5
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 5
- 229940117893 apigenin Drugs 0.000 description 5
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 5
- 235000008714 apigenin Nutrition 0.000 description 5
- 235000013793 astaxanthin Nutrition 0.000 description 5
- 239000001168 astaxanthin Substances 0.000 description 5
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 5
- 229940022405 astaxanthin Drugs 0.000 description 5
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229960002852 ellagic acid Drugs 0.000 description 5
- 235000004132 ellagic acid Nutrition 0.000 description 5
- ZGJKNMPTVDDRRH-UHFFFAOYSA-N heptatriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO ZGJKNMPTVDDRRH-UHFFFAOYSA-N 0.000 description 5
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 5
- 229940100243 oleanolic acid Drugs 0.000 description 5
- SECPZKHBENQXJG-BQYQJAHWSA-N palmitelaidic acid Chemical compound CCCCCC\C=C\CCCCCCCC(O)=O SECPZKHBENQXJG-BQYQJAHWSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 5
- 235000005875 quercetin Nutrition 0.000 description 5
- 229960001285 quercetin Drugs 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000494545 Cordyline virus 2 Species 0.000 description 4
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 239000010462 extra virgin olive oil Substances 0.000 description 3
- 235000021010 extra-virgin olive oil Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101100151951 Homo sapiens SARS1 gene Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000701460 JC polyomavirus Species 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- 235000002725 Olea europaea Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 2
- 108091007576 SARS-CoV-2 structural proteins Proteins 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 2
- 244000044822 Simmondsia californica Species 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 241000710951 Western equine encephalitis virus Species 0.000 description 2
- 241000101098 Xenotropic MuLV-related virus Species 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005727 virus proliferation Effects 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NKRAIOQPSBRMOV-NRMKKVEVSA-N (2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)C#C NKRAIOQPSBRMOV-NRMKKVEVSA-N 0.000 description 1
- QNQZPJLBGRQFDD-ZMSORURPSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N QNQZPJLBGRQFDD-ZMSORURPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 description 1
- CNPVJJQCETWNEU-CYFREDJKSA-N (4,6-dimethyl-5-pyrimidinyl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]methanone Chemical compound N([C@@H](COC)C=1C=CC(=CC=1)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C CNPVJJQCETWNEU-CYFREDJKSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- GVTFIGQDTWPFTA-UHFFFAOYSA-N 4-bromo-2-chloro-1-isothiocyanatobenzene Chemical compound ClC1=CC(Br)=CC=C1N=C=S GVTFIGQDTWPFTA-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 241000710946 Barmah Forest virus Species 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001493160 California encephalitis virus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000713889 Friend spleen focus-forming virus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000252870 H3N2 subtype Species 0.000 description 1
- 241001473385 H5N1 subtype Species 0.000 description 1
- 241000342557 H7N9 subtype Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000579048 Merkel cell polyomavirus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 241000700560 Molluscum contagiosum virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000122129 Roseolovirus Species 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- 241001137861 Rotavirus B Species 0.000 description 1
- 241001506005 Rotavirus C Species 0.000 description 1
- 241000373026 Rotavirus D Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001678561 Sarbecovirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000713880 Spleen focus-forming virus Species 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- SCTJKHUUZLXJIP-RUZDIDTESA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(=O)OCCCOCCCCCCCCCCCCCCCC)C=NC2=C1N SCTJKHUUZLXJIP-RUZDIDTESA-N 0.000 description 1
- VKXWOLCNTHXCLF-DXEZIKHYSA-N [(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate Chemical compound CC(C)C(=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@](COC(=O)C(C)C)(N=[N+]=[N-])O[C@H]1N1C(=O)N=C(N)C=C1 VKXWOLCNTHXCLF-DXEZIKHYSA-N 0.000 description 1
- DLGSOJOOYHWROO-WQLSENKSSA-N [(z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 description 1
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000001140 aloe barbadensis leaf extract Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940068561 atripla Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229950009668 balapiravir Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940014461 combivir Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960005449 daclatasvir Drugs 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 description 1
- 229960001418 dasabuvir Drugs 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229960002030 edoxudine Drugs 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960001447 fomivirsen Drugs 0.000 description 1
- XCWFZHPEARLXJI-UHFFFAOYSA-N fomivirsen Chemical compound C1C(N2C3=C(C(NC(N)=N3)=O)N=C2)OC(CO)C1OP(O)(=S)OCC1OC(N(C)C(=O)\N=C(\N)C=C)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(N=C(N)C=C2)=O)CC1OP(O)(=S)OCC(C(C1)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)OC1N1C=C(C)C(=O)NC1=O XCWFZHPEARLXJI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 229940112424 fosfonet Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960000374 ibacitabine Drugs 0.000 description 1
- WEVJJMPVVFNAHZ-RRKCRQDMSA-N ibacitabine Chemical compound C1=C(I)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 WEVJJMPVVFNAHZ-RRKCRQDMSA-N 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 108010018844 interferon type III Proteins 0.000 description 1
- 229940028894 interferon type ii Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960002461 ledipasvir Drugs 0.000 description 1
- VRTWBAAJJOHBQU-KMWAZVGDSA-N ledipasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 VRTWBAAJJOHBQU-KMWAZVGDSA-N 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 229950006243 loviride Drugs 0.000 description 1
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- STKUCSFEBXPTAY-YTECAPLWSA-N methyl (5e,6s)-5-ethylidene-4-[2-oxo-2-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate Chemical compound O([C@@H]\1OC=C(C(C/1=C\C)CC(=O)OC[C@@H]1[C@H]([C@H](O)[C@@H](O)[C@H](OCCC=2C=CC(O)=CC=2)O1)O)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O STKUCSFEBXPTAY-YTECAPLWSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960003152 metisazone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005389 moroxydine Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229940101771 nexavir Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- STKUCSFEBXPTAY-KCWGXYKVSA-N nuezhenoside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O STKUCSFEBXPTAY-KCWGXYKVSA-N 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 229960000518 ombitasvir Drugs 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002754 paritaprevir Drugs 0.000 description 1
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
- 229960000471 pleconaril Drugs 0.000 description 1
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 238000003385 ring cleavage reaction Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 229960002091 simeprevir Drugs 0.000 description 1
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 229950003429 sorbitan palmitate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229950006081 taribavirin Drugs 0.000 description 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 description 1
- 229960001355 tenofovir disoproxil Drugs 0.000 description 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 229950002244 tenofovir exalidex Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940111527 trizivir Drugs 0.000 description 1
- 229960000832 tromantadine Drugs 0.000 description 1
- UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940008349 truvada Drugs 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- 229960004626 umifenovir Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229950009860 vicriviroc Drugs 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/22—Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- This application generally relates to anti-viral compositions and, in particular, to olive extracts with anti-viral effect and method of use thereof.
- Viral infections such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, remain a serious problem.
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- auxiliary approaches for the preventions of viral infection and aggravation of symptoms.
- the present application addresses this demand by providing natural-derived compositions as supplemental agents for protection from pathogenic viruses, such as SARS- CoV-2.
- One aspect of the present application relates to a method for preventing, treating, or ameliorating symptoms, of a viral infection in a subject.
- the method comprises the step of administering to the subject an effective amount of an olive component composition, wherein the olive component composition comprises one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10- hydroxyoleuropein, and 10-hydroxy ligstroside; vanillic acid, 3-hydroxy, 4- metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic
- Another aspect of the present application relates to a method for preventing or reducing surface transmission of a virus.
- the method comprises the step of applying an effective amount of an olive component composition to a surface for a period of time to inactivate the virus on the surface, wherein the olive component composition comprises one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, such as oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3- hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, ca
- the composition comprises an olive component composition, wherein the olive component composition comprises: (1) one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxyoleuropein, and 10- hydroxyligstroside; vanillic acid, 3-hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy- benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA- EDA, lignanes, flavonoids, elenolic acid,
- the antiviral composition comprises an olive component composition, wherein the olive component composition comprises: one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10- hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3-hydroxy, 4- metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids
- FIG. 1 is a schematic illustration of an exemplary process for preparing a hydroxytyrosol (HT)-rich aqueous olive pulp extract (HIDROX®).
- HT hydroxytyrosol
- HIDROX® hydroxytyrosol
- FIG. 2 panel A is a schematic illustration of an experimental protocol for evaluating the time- and concentration-dependent virucidal activity of HIDROX® against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- FIG. 3 shows the time- and concentration-dependent virucidal activity of HIDROX® against SARS-CoV-2.
- SARS-CoV-2 was mixed with HIDROX®.
- the final concentrations of HIDROX® in the mixture were 0.45, 0.90, and 4.50 mg/mL (FIG. 3, panel A) or 5.63 and 11.25 mg/mL (FIG, 3, panel B).
- PBS was mixed with the viral suspension. The mixtures were incubated at 25 °C for 0.5-24 h (Panel A) or 5 min (Panel B) after which the viral titers were evaluated.
- FIG. 4 shows an experimental protocol for evaluating the time-dependent virucidal activity of HIDROX® against four SARS-CoV-2 variant strains, namely the UK variant, the Brazilian variant the South African variant and the Delta variant.
- FIG. 5 shows the time-dependent virucidal activity of HIDROX® against the four SARS-CoV variants according to the experimental protocol depicted in FIG. 4. Student’s /-test was performed to evaluate the statistically significant difference between the PBS group and each test group; ** p ⁇ 0.01; *** p ⁇ 0.001.
- FIG. 6, panel A depicts an experimental protocol for evaluating the comparative virucidal activities of HIDROX® and HT against SARS-CoV-2.
- HIDROX® and HT were mixed with SARS-CoV-2 at 0.90 mg/ml, inoculated to cells and incubated at 25 °C for 3 or 24 hr.
- the final concentration of HIDROX® in the mixture was 0.90 mg/mL; the final concentration of HT in the mixtures were 0.90 mg/mL and 0.05.
- PBS was mixed with the viral suspension as the diluent control. Following the incubation period, viral titers were determined.
- FIG. 6, panel B shows the results of the experiment depicted in FIG. 6, panel A.
- FIG. 7, panel A shows an experimental protocol for examining the direct virucidal activity of HIDROX® against SARS-CoV-2 at various concentrations (6.25 - 100 mg/ml).
- FIG. 7, panel B shows the virucidal activity of HIDROX® at various concentrations in accordance with the schematic diagram in FIG. 7.
- FIG. 8 shows an experimental protocol for evaluating the inhibitory effect of HIDROX® (pH 7.4) on virus proliferation in host cells.
- FIG. 9 shows the results of the experiment described in FIG. 8.
- FIG. 10 shows an experimental protocol for examining the direct virucidal activity of HIDROX® against SARS-CoV-2 at low concentrations (0.5 - 5.0 mg/ml).
- FIG. 11 shows the results of the experiment described in FIG. 10.
- FIG. 12 shows the cytotoxicity of HT (0 - 50 pg/ml) compared to
- HIDROX® (0 - 250 pg/ml).
- FIG. 13 panel A shows an experimental protocol for comparing the virucidal activities of HIDROX® and HT against SARS-CoV-2 at 1.0 mg/ml and 0.05 mg/ml.
- FIG. 13, panel B shows the result of the experiment described in panel A.
- FIG. 14 shows the time- and concentration-dependent virucidal activity of HIDROX®-containing cream against SARS-CoV-2.
- SARS-CoV-2 was covered by 0%, 2%, 5%, and 10% HIDROX®-containing cream-coated films and incubated for 10 min-6 h at 25 °C. After the predetermined reaction times, the viral solutions were recovered and the viral titers were determined.
- FIG. 15 shows the impact of HIDROX® and HT on SARS-CoV-2 proteins.
- panel A SARS-CoV-2 was mixed with HIDROX® or HT. The final concentrations of HIDROX® and HT in each mixture was 0.90 mg/mL.
- PBS was mixed with the SARS-CoV-2 as a diluent control. The mixtures were incubated at 25 °C for 0 (no reaction time) or 24 h, and then Western blotting was performed.
- panel A the images on the left, middle, and right show the results of Western blotting to detect S protein SI subunit, S protein S2 subunit, and N protein, respectively.
- panel B the recombinant S protein RBD or N protein was mixed with PBS, HIDROX®, or HT. The final concentration of HIDROX® and HT in each mixture was 0.90 mg/mL. The final concentration of recombinant viral proteins in each mixture was approximately 10 ⁇ . g/mL The mixtures were incubated at 25 °C for 0 (no reaction time) or 24 h and then Western blotting was performed. The images on the left and right show the results of Western blotting to detect S protein RBD and N protein, respectively.
- FIG. 16 shows the impact of HIDROX® or HT on carbohydrate chains expressed on the S protein.
- glycosylated and deglycosylated forms of recombinant S protein SI subunit, RBD, and S2 subunit were mixed with PBS, HIDROX®, or HT.
- the final concentration of HIDROX® and HT in each mixture was 0.90 mg/mL.
- the final concentration of recombinant S proteins in the mixtures was approximately 10 . ⁇ g/mL
- the mixtures were incubated at 25 °C for 24 h and then Western blotting was performed.
- the images on the left, middle, and right show the glycosylated and unglycosylated forms of the SI subunit, RBD, and S2 subunit, respectively.
- FIG. 17 shows the impact of HIDROX® and HT on SARS-CoV-2 genome.
- SARS-CoV-2 was mixed with HIDROX® or HT at a concentration of 0.90 mg/mL.
- FIG. 18 shows the cytotoxicity of HT (0 - 500 pg/ml) compared to HIDROX® (0 - 500 pg/ml) in MDCK cells, the host cells for influenza (H1N1) in the experiment described in FIG. 19.
- FIG. 19 panel A shows an experimental protocol for evaluating the virucidal activity of HIDROX® against influenza-infected MDCK cells at various different concentrations and incubation periods.
- FIG. 20 shows GC chromatographic profiles of (A) OLIVENOLTM (in column 9.0 pg), vegetation waters (B) CR43 (10.0 pg) and (C) CR21 (8.0 pg), and (d) polar fraction from 100 ml of Moraiolo extra-virgin olive oil (17.8 pg). Peaks: 1, tyrosol; 2, vanillic acid; 3, hydroxytyrosol (i.e. HT); 4, 3,4-dihydroxybenzoic acid; 5, citric acid; 6, syringic acid; 7, gallic acid.
- FIG. 21 shows GC chromatographic profiles of (A) not treated OVW at time O (in column 12.0 pg), (B) not treated OVW after 6 months (12.0 pg) and (C) treated OVW after 6 months (10.0 pg). Peaks: 1, tyrosol; 2, vanillic acid; 3, hydroxy tyrosol; 4, 3,4- dihydroxybenzoic acid; 5, citric acid; 6, syringic acid; 7, gallic acid; 8, caffeic acid; 9, 3- hydroxy, 4-metoxy-phenylacetic acid; 10, gentisic acid.
- FIG. 22 panel A shows an experimental protocol for evaluating inhibitory effects of Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 22, panel B shows the results of the experiment in FIG. 22, panel A.
- FIG. 23 panel A shows an experimental protocol for evaluating inhibitory effects of HIDROX® on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 23, panel B shows the results of the experiment in FIG. 23, panel A.
- FIG. 24 shows an experimental protocol for evaluating antiviral activity of cells pre-treated with Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 24, panel B shows the results of the experiment in FIG. 24, panel A.
- FIG. 25 shows an experimental protocol for evaluating antiviral activity of cells pre-treated with HIDROX® on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 25, panel B shows the results of the experiment in FIG. 25, panel A.
- FIG. 26 panel A shows an experimental protocol for evaluating direct virucidal activity of Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 26, panel B shows the results of the experiment in FIG. 26, panel A.
- FIG. 27, panel A shows an experimental protocol for evaluating direct virucidal activity of HIDROX® on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 27, panel B shows the results of the experiment in FIG. 27, panel A.
- FIG. 28, panel A shows an experimental protocol for evaluating the effects of acidic pH on HIDROX®’s virucidal activity in suppressing SARS-CoV-2 proliferation in cells.
- FIG. 28, panel B shows the results of the experiment in FIG. 28, panel A.
- FIG. 29, panel A shows an experimental protocol for evaluating the effects of HIDROX® in suppressing the proliferation of the Delta variant of SARS-CoV-2 in cells.
- FIG. 29, panel B shows the results of the experiment in FIG. 29, panel A.
- a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- compositions of the invention e.g., any nucleic acid or protein encoded thereby; any method of production; any method of use; etc.
- any particular embodiment of the compositions of the invention can be excluded from any one or more claims, for any reason, whether or not related to the existence of prior art.
- the phrases “administered in combination” or “combined administration” means that two or more agents are administered to a subject at the same time or within an interval such that there may be an overlap of an effect of each agent on the patient. In some embodiments, they are administered within about two weeks, one week, 2-5 days, one week, 60 min, 30 min, 15 min, 10 min, 5 min, or 1 min of one another. In some embodiments, the administrations of the agents are spaced sufficiently closely together such that a combinatorial (e.g., a synergistic) effect is achieved.
- a combinatorial e.g., a synergistic
- the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
- control individual is an individual who is not afflicted with the same virus as the individual being treated, who is about the same age as the individual being treated (to ensure that the stages of the disease in the treated individual and the control individual(s) are comparable).
- the individual (also referred to as "patient” or “subject”) being treated may be a fetus, infant, child, adolescent, or adult human.
- an effective amount refers to an amount sufficient to provide antiviral activity against SARS-CoV-2, as compared to responses (or lack thereof) obtained without administration of the antiviral composition.
- the terms, "improve”, “increase,” “reduce”, “ameliorate,” as used in this context, indicate values or parameters relative to a baseline measurement, such as a measurement in the same individual prior to initiation of the treatment described herein, or a measurement in a control individual (or multiple control individuals) in the absence of the treatment
- phrases "pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio when administered to an animal or a human, as appropriate.
- pharmaceutically acceptable carrier refers to pharmaceutically- acceptable materials, compositions or vehicles, including any and all solvents, solubilizers, fillers, diluents, stabilizers, surfactants, binders, absorbents, bases, buffering agents, excipients, lubricants, controlled release vehicles, diluents, emulsifying agents, encapsulating materials, humectants, lubricants, gels, dispersion media, coatings, antibacterial or antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- solvents solubilizers
- fillers diluents, stabilizers, surfactants, binders, absorbents, bases, buffering agents, excipients, lubricants, controlled release vehicles, diluents, emulsifying agents, encapsulating materials, humectants, lubricants, gels, dispersion media, coatings, antibacterial or antifungal agents
- the term "preventing" refers to partially or completely delaying onset of a viral infection, such as a SARS-CoV-2 infection, disease, disorder and/or condition thereof; partially or completely delaying onset of one or more symptoms, features, or clinical manifestations of a viral infection, disease, disorder, and/or condition thereof; partially or completely delaying onset of one or more symptoms, features, or manifestations of a viral infection, disorder, and/or condition thereof; partially or completely delaying progression from viral infection, disease, disorder and/or condition thereof; and/or decreasing the risk of developing pathology associated with viral infection, disease, disorder, and/or condition thereof.
- a viral infection such as a SARS-CoV-2 infection, disease, disorder and/or condition thereof
- partially or completely delaying onset of one or more symptoms, features, or clinical manifestations of a viral infection, disease, disorder, and/or condition thereof partially or completely delaying onset of one or more symptoms, features, or manifestations of a viral infection, disorder, and/or condition thereof
- SARS-CoV-2 refers to betacoronavirus believed to be of lineage B (sarbecovirus). SARS-CoV-2 was first identified in Wuhan, Hubei province, China, in late 2019. As used herein, the term “SARS-CoV-2” refers to both the “SARS-CoV-2 original strain” and variants of the SARS-CoV-2 original strain.
- variant of SARS-CoV-2 and “SARS-CoV-2 variant” are used interchangeably with reference to SARS-CoV-2 strains that differ from original or progenitor SARS-CoV-2 strains by one or more nucleotides in the viral genome.
- variants of the SARS-CoV-2 original strain may be further divided into subgroups of variants, such as Alpha variants, Beta variants, Delta variants, Delta plus variants, omicron variants and the like, which have accumulated enough mutations to represent separate branches on the family tree.
- SARS-CoV-2 spike protein refers to the spike protein of SARS-CoV-2, which plays a key role in the receptor recognition and cell membrane fusion process.
- SARS-CoV-2 SI protein refers to the SI subunit of the SARS-CoV-2 spike protein.
- the term “subject” refers to any human or non-human mammal to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes.
- "subject” refers to a human or non-human mammal at any stage of development.
- the non-human mammal is, for example, a primate, monkey, rodent, mouse, rat, rabbit, monkey, dog, cat, sheep, pig, cattle, or sheep.
- the animal is a transgenic or genetically-engineered mammal.
- the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% in relation to a reference property of interest).
- a characteristic or property of interest e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% in relation to a reference property of interest.
- treat and “treatment” refer to the amelioration of one or more symptoms associated with a coronavirus infection; prevention or delay of the onset of one or more symptoms of a viral infection; and/or lessening of the severity or frequency of one or more symptoms of the infection.
- an olive component (OC) composition having anti-viral activity refers to an olive component (OC) composition having anti-viral activity.
- Olive component (OC) refers to chemical compounds, complexes or materials that are present in olives, the fruit of Olea europaea, or in products derived from olives, such as olive oil vegetation waters and the acidic hydrolysis products thereof.
- An OC may be obtained from a non-olive fruit or plant, or by chemical synthesis.
- the OC composition of the present application comprises one or more polyphenols.
- Polyphenols are a group of natural products occurring in tissues of all higher plants. Polyphenols are characterized by the presence of large multiples of phenol structural units. The number and characteristics of these phenol structures underly the unique physical, chemical, and biological (e.g., metabolic, toxic, and therapeutic) properties of particular members of the class. Polyphenols may be broadly classified as phenolic acids, flavonoids, stilbenes, and lignans. Of the various plants, the olive (Olea europaea L.) contains a large number of polyphenols.
- Exemplary polyphenol compounds in olives for use in the OC compositions of the present application include, but are not limited to, hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3-hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alpha-tocopherol, verbascoside, pinoresinol lignan,
- the OC composition of the present application comprises hydroxytyrosol, and one or more polyphenols selected from the group consisting of tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3- hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alpha-tocopherol, verbascoside, pinoresinol, and one or more polyphenols selected
- the OC composition of the present application comprises (1) one or more polyphenols selected from the group consisting of tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA- EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10- hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3-hydroxy, 4- metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alphatocopherol, verbascoside, pinoresinol lignan, rutin flavo
- the OC composition of the present application further comprises one or more non-phenolic compounds.
- non-phenolic compounds in olives for use in the composition of the present application include, but are not limited to, D-fructose, glucofuranoside, glucopyranoside, dihydroxyacetone, malic acid, trihydroxybutyric acid, glucitol, glycerol, propanoic acid, xylonic acid, xylulose, xylitol, arabinose, ribose, deoxyribose, galactopyranoside, ketogluconic acid and galactofuranose.
- the OC composition of the present application comprises one or more compounds selected from the group consisting of hydroxytyrosol, tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid, syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, lycopene, apigenin, rutin, [3-carotene, 9-hexadecenoic acid, cholestan-3-ol, 2- methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3-hydroxy, 4-metoxy- phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1-heptatriacotanol,
- the OC composition of the present application comprises (1) hydroxytyrosol, (2) propanoic acid, and (3) one or more compounds selected from the group consisting of tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid, syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, lycopene, apigenin, rutin, [3-carotene, 9- hexadecenoic acid, cholestan-3-ol, 2-methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3-hydroxy, 4-metoxy-phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1-h
- the OC composition of the present application comprises (1) hydroxytyrosol, (2) propanoic acid, and (3) one or more compounds selected from the group consisting of tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid, syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, lycopene, apigenin, rutin, [3-carotene, 9- hexadecenoic acid, cholestan-3-ol, 2-methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3-hydroxy, 4-metoxy-phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1-h
- the OC composition of the present application comprises (1) hydroxy tyrosol; and (2) one or more compounds selected from the group consisting of tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid, syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, lycopene, beta-carotene, apigenin, rutin, 9-hexadecenoic acid, cholestan-3-ol, 2-methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3- hydroxy, 4-metoxy-phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1- heptatriacotan
- the OC composition of the present application comprises (1) hydroxy tyrosol; and (2) one or more compounds selected from the group consisting of tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid, syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, apigenin, rutin, lycopene, [3-carotene, 9-hexadecenoic acid, cholestan-3- ol, 2-methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3-hydroxy, 4- metoxy-phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1-heptatriacotan
- the OC composition of the present application comprises 0.1-50 wt %, 0.1-0.2 wt %, 0.1-0.5 wt %, 0.1-1 wt %, 0.1-2 wt %, 0.1-5 wt%, 0.1- 10 wt %, 0.1-20 wt %, 0.2-0.5 wt%, 0.2-1 wt %, 0.2-2 wt %, 0.2-5 wt%, 0.2-10 wt %, 0.2-20 wt %, 0.2-50 wt%, 0.5-1 wt %, 0.5-2 wt %, 0.5-5 wt%, 0.5-10 wt %, 0.5-20 wt %, 0.5-50 wt%, 1-2 wt %, 1-5 wt%, 1-10 wt %, 1-20 wt %, 1-50 wt%, 2-5 wt%, 2-10 wt %, 2
- the phenolic compounds of the above-described OC composition comprise (1) hydroxytyrosol in the range of 10-70 wt%, 10-15 wt%, 10-20 wt%, 10-25 wt%, 10-30 wt%, 10-35 wt%, 10-40 wt%, 10-45 wt%, 10-50 wt%, 10-55 wt%, 10-60 wt%, 10-65 wt%, 15-20 wt%, 15-25 wt%, 15-30 wt%, 15-35 wt%, 15-40 wt%, 15-45 wt%, 15-50 wt%, 15-55 wt%, 15-60 wt%, 15-65 wt%, 15-70 wt%, 20-25 wt%, 20-30 wt%, 20-35 wt%, 20-40 wt%, 20-45 wt%, 20-50 wt%, 20-55 wt%, 20-60
- phenolic compounds of the above-described OC composition comprise about 35-45 wt% hydroxytyrosol, 5-10 wt% oleuopein and 0.1-0.5 wt% tyrosol.
- the OC composition of the present application comprises an aqueous olive pulp extract, a concentrated aqueous olive pulp extract, or a dried aqueous olive pulp extract. In some embodiments, the OC composition of the present application comprises an aqueous olive pulp extract treated with acid hydrolysis. In some embodiment, the OC composition of the present application comprises one or more of the compounds in the amount shown in Table 1.
- the OC composition of the present application comprises one or more of the compounds in the amount shown in Table 2. [0079] Table 2. Composition of the OC composition of the present application
- an anti-viral formulation comprising the OC composition of the present application.
- the anti-viral formulation is a nutraceutical.
- the antiviral formulation is formulated as a moisturizer lotion or cream for topical application.
- the anti-viral formulation is formulated as a dietary supplement.
- the anti-viral formulation is formulated as an aerosol for inhalation.
- the anti-viral formulation is a pharmaceutical composition comprising the OC composition of the present application and a pharmaceutically acceptable carrier.
- the anti-viral formulation comprise the OC composition of the present application in an amount in the range of 0.01-99.9 wt%, 0.01-90 wt%, 0.01-60 wt%, 0.01-30 wt%, 0.01-10 wt%, 0.01-3 wt%, 0.01-1 wt%, 0.01-0.3 wt%, 0.01-0.1 wt%, 0.01-0.03 wt%, 0.03-99.9 wt%, 0.03-90 wt%, 0.03-60 wt%, 0.03-30 wt%, 0.03-10 wt%, 0.03-3 wt%, 0.03-1 wt%, 0.03-0.3 wt%, 0.03-0.1 wt%, 0.1-99.9 wt%, 0.1-90 wt%, 0.1-60 wt%, 0.1-30 wt%, 0.1-10 wt%, 0.1-3 wt%, 0.1-1
- the anti-viral formulation of the present application is a moisturizer comprising the OC composition of the present application and one or more components selected from the group consisting of Aloe Barbadensis Leaf Juice, Olive Oil, Glycerin, Stearyl Alcohol, Glyceryl Stearate, PEG-100 Stearate, Simmondsia Chinensis (Jojoba), Seed Oil, Sorbitan Olivate, Lauryl Laurate, Sorbitan Stearate, Glycol Distearate, Sodium Hyaluronate, Allantoin, Cetyl Palmitate, Sorbitan Palmitate, Cetearyl Olivate, Camellia Sinensis Leaf Extract, Xanthan Gum, Phenoxyethanol, Capryl Glycol, Ethylhexylglycerin, Hexylene Glycol and Citric Acid.
- Aloe Barbadensis Leaf Juice Olive Oil
- Glycerin Stearyl Alcohol
- Glyceryl Stearate PEG-100 Stearate
- the anti-viral formulation of the present application comprises one or more ingredients in amounts described in Table 3. In some embodiments, the anti-viral formulation of the present application comprises all the ingredients in amounts described in Table 3.
- the anti-viral formulation of the present invention is formulated as a pharmaceutical composition comprising the OC composition of the present application, at least one pharmaceutically acceptable carrier, and optionally one or more secondary pharmaceutically active compounds.
- an olive component contains an acidic group as well as a basic group
- the compound can form internal salts, which can be present in the OC compositions and anti-viral formulations described herein.
- an olive component contains a hydrogendonating heteroatom (e.g., NH)
- salts are contemplated to cover isomers formed by transfer of said hydrogen atom to a basic group or atom within the molecule.
- Pharmaceutically acceptable salts of the olive component include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts.
- Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosy
- Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases can also be formed, for example, hemisulphate and hemicalcium salts.
- suitable salts see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002), incorporated herein by reference.
- the pharmaceutically acceptable carrier includes, but is not limited to, diluents, binders, lubricants, disintegrators, fillers, pH modifying agents, preservatives, antioxidants, solubility enhancers, and coating compositions.
- the pharmaceutical composition of the present invention can be prepared in a manner known per se, which usually involves mixing the OC composition according to the disclosure with one or more pharmaceutically acceptable carriers, and, if desired, in combination with other pharmaceutical active compounds when necessary under aseptic conditions.
- a manner known per se which usually involves mixing the OC composition according to the disclosure with one or more pharmaceutically acceptable carriers, and, if desired, in combination with other pharmaceutical active compounds when necessary under aseptic conditions.
- the pharmaceutical composition is typically made in a unit dosage form, and can be suitably packaged, for example in a box, blister, vial, bottle, sachet, ampoule or in any other suitable single-dose or multi-dose holder or container (which can be properly labeled); optionally with one or more leaflets containing product information and/or instructions for use.
- unit dosages will contain from 1 to 2000 mg (e.g., 10, 25, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 mg) per unit dosage.
- the OC composition or the anti-viral formulation of the present application olive compounds can be administered by a variety of routes including the oral, ocular, rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal routes, depending mainly on the specific preparation used.
- the OC composition or the anti-viral formulation of the present application will generally be administered in an "effective amount", by which is meant any amount of each olive compound that, upon suitable administration, is sufficient individually, collectively or synergistically to achieve the desired therapeutic or prophylactic effect in the subject to which it is administered.
- the anti-viral formulations described herein can be formulated for modified or controlled release.
- controlled release dosage forms include extended-release dosage forms, delayed release dosage forms, pulsatile release dosage forms, and combinations thereof.
- Formulations with different drug release mechanisms described above can be combined in a final dosage form comprising single or multiple units. Examples of multiple units include, but are not limited to, multilayer tablets and capsules containing tablets, beads, or granules
- An immediate release portion can be added to the extended-release system by means of either applying an immediate release layer on top of the extended-release core using a coating or compression process or in a multiple unit system such as a capsule containing extended and immediate release beads.
- the OC composition of the present application is formulated for topical administration.
- Suitable topical dosage forms include lotions, creams, ointments, and gels.
- a "gel” is a semisolid system containing a dispersion of the active agent, i.e., olive compounds in a liquid vehicle that is rendered semisolid by the action of a thickening agent or polymeric material dissolved or suspended in the liquid vehicle.
- the liquid can include a lipophilic component, an aqueous component or both.
- Some emulsions can be gels or otherwise include a gel component.
- Some gels, however, are not emulsions because they do not contain a homogenized blend of immiscible components.
- the OC composition of the present application can be stored as a lyophilized powder under aseptic conditions and combined with a sterile aqueous solution prior to administration.
- the aqueous solution used to resuspend the OC composition can contain pharmaceutically acceptable auxiliary substances as required to approximate physical conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, as discussed above.
- the OC composition can be stored as a suspension, preferable an aqueous suspension, prior to administration.
- Another aspect of the present application relates to a method of preventing, treating, or ameliorating symptoms of a viral infection with the OC composition or formulation of the present application.
- the method comprises the step of administering to a subject in need of such treatment, an effective amount of the OC composition or formulation of the present application.
- the subject is infected with, or is at risk of being infected by, a coronavirus.
- the subject is infected with, or is at risk of being infected by a human SARS CoV-2 isolate, such as Wuhan-Hu-1 (NC_045512.2) and any CoV-2 isolates comprising a genomic sequence set forth in GenBank Accession Nos., such as MT079851
- the viral infection caused by a.l, MT470137.1, MT121215.1, MT438728.1, MT470115.1, MT358641.1, MT449678.1, MT438742.1, LC529905.1, MT438756.1, MT438751.1, MT460090.1, MT449643.1, MT385425.1, MT019529.1, MT449638.1, MT374105.1, MT449644.1, MT385421.1, MT365031.1,
- influenza A virus including subtype H1N1, H3N2, H7N9, or H5N1, influenza B virus, influenza C virus, rotavirus A, rotavirus B, rotavirus C, rotavirus D, rotavirus E, human coronavirus, SARS coronavirus, MERS coronavirus, human adenovirus types (HAdV-1 to 55), human papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, parvovirus B19, molluscum contagiosum virus, JC virus (JCV), BK virus, Merkel cell polyomavirus, coxsackie A virus, norovirus, Rubella virus, lymphocytic choriomeningitis virus (LCMV), Dengue virus, Zika virus, chikungunya, Eastern equine ence
- influenza B virus influenza C virus
- rotavirus A rotavirus B
- rotavirus C
- the OC composition or formulation of the present application be administered by any route, including but not limited to any of the various parenteral, gastrointestinal, inhalation, and topical (epicutaneous) routes of administration.
- Parenteral administration generally involves injections or infusions and includes, for example, intravenous, intraarterial, intratumoral, intracardiac, intramuscular, intravesicular (e.g., to the bladder), intracerebral, intracerebroventricular, intraosseous infusion, intravitreal, intaarticular, intrathecal, epidural, intradermal, subcutaneous, transdermal, and intraperitoneal administration.
- Gastrointestinal administration includes oral, buccal, sublingual and rectal administration. The route of administration may involve local or systemic delivery of the OC composition or formulation.
- the OC composition of the present application are delivered transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the pharmaceutical compositions are formulated into ointments, salves, gels, or creams as generally known in the art.
- a therapeutically effective amount of an olive compound composition administered will be in a weight range of about 1 ng/kg body weight/day to about 100 mg/kg body weight/day whether by one or more administrations.
- the OC composition or formulation of the present application is administered in weight range from about 1 ng/kg body weight/day to about 1 pg/kg body weight/day, 1 ng/kg body weight/day to about 100 ng/kg body weight/day, 1 ng/kg body weight/day to about 10 ng/kg body weight/day, 10 ng/kg body weight/day to about 1 pg/kg body weight/day, 10 ng/kg body weight/day to about 100 ng/kg body weight/day, 100 ng/kg body weight/day to about 1 pg/kg body weight/day, 100 ng/kg body weight/day to about 10 pg/kg body weight/day, 1 pg/kg body weight/day to about 10 pg/kg body weight/day, 1 pg/kg body weight/day to about 10
- the OC composition or formulation of the present application is administered every 4, 6, 8, 12 or 24 hours for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 days. In some embodiments, the OC composition or formulation of the present application is administered every 1, 2, 3, 4, 5, 6 or 7 days for a period of 3, 7, 14, 21 or 28 days.
- the OC composition of the present application is formulated as a cream or lotion or moisturizer.
- the method comprises the step of applying the cream or lotion to a surface of a skin for a period of 1-60 min, 1-45 min, 1-30 min, 1-15 min, 1-10 min, 1-5 min, 5-60 min, 5-45 min, 5-30 min, 5-15 min, 5-10 min, 10-60 min, 10-45 min, 10-30 min, 10-15 min, 30-60 min, 30-45 min, 45-60 min.
- Another aspect of the present application relates to a method for preventing viral transmission.
- the method comprises the step of treating a surface with an effective amount of an anti-viral composition comprising the OC composition of the present application for a desired period of time to inactive virus on the surface.
- the anti-viral composition is formulated as a cream, lotion or moisturizer.
- the anti-viral composition is formulated as a moisturizer with ingredients shown in Table 3.
- Another aspect of the present application relates to a method for preventing viral infection or ameliorating a symptom of a viral infection in a subject.
- the method comprises the step of administering to the subject an effective amount of a dietary supplement comprising the OC composition of the present application
- Another aspect of the present application relates to a method for preventing viral infection or ameliorating a symptom of a viral infection in a subject.
- the method comprises the step of administering to the subject an effective amount of the OC composition of the present application, wherein the OC composition is formulized in an aerosol and wherein the aerosol is administered by inhalation.
- the method of the present application further comprises a step of administering to the subject one or more secondary active compounds.
- the one or more secondary active compounds may be administered before, after or concurrently with the OC composition or formulation of the present application.
- the secondary active compounds include, but are not limited to, other antiviral agents, analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, anxiolytics, sedatives, hypnotics, antipsychotics, bronchodilators, anti-asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, anorectics, and anti-narcoleptics.
- antiviral agents include, but are not limited to, abacavir, acyclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, balapiravir, BCX4430, boceprevir, cidofovir, combivir, daclatasvir, darunavir, dasabuvir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, favipiravir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, GS-5734, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon
- SARS-CoV-2 JPN/TY/WK-521 strain
- variant strains of SARS-CoV-2 including UK variant strain (hCoV-19/Japan/QHN001/2020), Brazilian variant strain (hCoV- 19/Japan/TY7-501/2021), South African variant strain (hCoV-19/Japan/TY8-612/2021), Delta variant strain (hCoV-19/Japan/TYl l-927-Pl/2021) were obtained from the National Institute of Infectious Diseases (Tokyo, Japan).
- the VeroE6/TMPRSS2 cell line which was established in the National Institute of Infectious Diseases, was obtained from the Japanese Collection of Research Bioresources (Osaka, Japan, Cell No.
- VeroE6/TMPRSS2 cells were cultured in Dulbecco’s Modified Eagle’s minimal essential medium (DMEM; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% fetal bovine serum, 2 mM L-glutamine (FUJIFILM Wako Pure Chemical Co., Osaka, Japan), 0.15% NaHCOi (FUJIFILM Wako Pure Chemical Co.), 2 ⁇ g/ ammLphotericin B (Bristol- Myers Squibb Co., New York, NY, USA), 100 ⁇ g/m kaLnamycin (Meiji Seika Pharma Co., Ltd., Tokyo, Japan), and 100 ⁇ g/mL G418 disulfate aqueous solution (Nacalai Tesque Inc., Kyoto, Japan).
- DMEM Modified Eagle’s minimal essential medium
- fetal bovine serum 2 mM L-glutamine
- FUJIFILM Wako Pure Chemical Co.
- VGM viral growth medium
- Viral stocks were obtained from cell culture supernatants (VGM containing SARS-CoV-2) and stored at -80°C [viral titers: 6.90 to 7.25 logw 50% tissue culture infective doses (TCIDso)/mL].
- SARS-CoV-2 was handled in the biosafety level 3 facility.
- Olives are crushed in water to form an olive slurry.
- the aqueous portion of the slurry (“vegetation water” or “olive juice”) is separated, collected and acidified with food grade citric acid to a specific pH range.
- the acid-treated olive juice is filtrated and freeze dried to produce a powder comprising about 12% phenolic compounds (HIDROX® freeze-dried powder 12%).
- HIDROX® solution 1 g of HIDROX® 12% (Oliphenol LLC., CA, USA) powder was dissolved in 10 mL of phosphate- buffer saline (PBS) and a centrifugation (850 x g, 10 min) was performed. The aqueous layer collected was stored at -30°C and used as the stock of 100 mg/mL HIDROX® solution.
- PBS phosphate- buffer saline
- HT 3 -Hydroxy tyrosol
- 1 g of 3-Hydroxytyrosol was dissolved in 10 mL of PBS and the stock of 100 mg/mL HT solution was also stored at -30°C.
- Various concentrations of HIDROX® and HT solutions were prepared by diluting the stock solutions with PBS before using.
- OLIVENOLTM plus + Healing Moisturizer (Oliphenol, LLC) containing 2%, 5%, or 10% HIDROX® was prepared as the HIDROX®-containing cream.
- the HIDROX®-free (0%) base ingredients of OLIVENOLTM plus + healing Moisturizer was used as the base control.
- SARS-CoV-2 solution (7.25 logw TCID 50 /mL) was mixed with 9 times the amount of HIDROX® solution or HT solution.
- these recombinant viral proteins were mixed with HIDROX® solution or HT solution.
- the product information of these recombinant proteins is shown in Table 4. The final concentration of HIDROX® and HT in the mixture was 0.90 mg/mL.
- PBS was mixed with the viral solution or recombinant proteins.
- the final concentration of recombinant proteins in the mixture was approximately 10 ⁇ g./ ImnL the experiment analyzing the interaction of HIDROX® or HT with carbohydrate chains expressed on S proteins, approximately 10 ⁇ g/mL of recombinant S proteins (SI subunit, RBD, and S2 subunit) were incubated at 37°C overnight with or without 6500 units/mL of PNGase F PRIMETM Glycosidase (N-Zyme Scientifics LLC., PA, USA).
- the glycosidase-treated or untreated proteins were mixed with PBS, HIDROX® solution, or HT solution.
- the final concentration of HIDROX® and HT in the mixtures was 0.90 mg/mL.
- SARS-CoV-2 solution (7.25 logw TCID 50 /mL) was mixed with 9 times the amount of HIDROX® solution or HT solution. The final concentration of HIDROX® and HT in the mixture was 0.90 mg/mL.
- PBS was mixed with the viral solution. These mixtures were placed at 25 °C for 0 hr (no reaction time) or 24 hr and then RNA was extracted using ISOGEN-LS (Nippon Gene, Tokyo, Japan) according to the manufacturer protocol. Five-hundred ng of RNA thus obtained was reverse transcribed using FastGene cDNA Synthesis 5x ReadyMix OdT (NIPPON Genetics Co, Ltd., Tokyo, Japan).
- real-time RT-PCR was performed using EagleTaq Master Mix with ROX (F. Hoffmann-La Roche Ltd., Basel, Switzerland) with the primers and probe as described in Shirato K et al., Jpn. J. Infect. Dis 2020, 73:304-307.
- the real-time RT-PCR conditions were: 50°C for 2 min; 95 °C for 10 min; 45 cycles of 95°C for 15 sec and 50°C for 1 min.
- HIDROX® 12% (Oliphenol LLC., CA, USA) was dissolved in 10 mL of phosphate-buffered saline (PBS) and centrifuged at 850 x g for 10 min. The aqueous layer collected was stored at -30°C as a 100 mg/mL HIDROX® stock solution. A 1.0 mg/mL of HIDROX® solution was prepared by dilution of the stock solutions with PBS. PBS was used as a control solution.
- PBS phosphate-buffered saline
- a viral solution (VGM containing variant SARS-CoV-2) was mixed with nine volumes of 1.0 mg/mL of HIDROX® solution. The final concentrations of HIDROX® in the mixture was 0.9 mg/mL.
- PBS was mixed with the viral solution. The mixtures were incubated at 25 °C for 3 or 24 h and then inoculated into the cells, and a tenfold serial dilution was performed. After a 3 d incubation of the cells at 37°C, a cytopathic effect was observed, and the viral titer ( log 10 TCID 50 /mL) was calculated using the Behrens- Karber method.
- the detection limit of the viral titer in each test solution group was determined based on the cytotoxicity of each test solution.
- the detection limits of the viral titers in the groups treated with PBS or HIDROX® solution were set to 1.25 and 2.25 logic TCID 50 /mL, respectively.
- Student’s t test was performed to determine statistically significant differences between a control group (e.g, PBS) and each test sample group (e.g., HIDROX®- treated). P values of less than 0.05 were considered statistically significant.
- Example 2 Time- and concentration-dependent virucidal activity of HIDROX® solution against SARS-CoV-2.
- a HIDROX® solution was prepared in accordance with the schematic illustration depicted in FIG. 1 and the specific method steps outlined in Example 1.
- the virucidal activity of the HIDROX® solution against SARS-CoV-2 was evaluated in accordance with the experimental protocol depicted in FIG. 2 and the corresponding method steps below. Briefly, a SARS-CoV-2 solution (7.25 logw TCID 50 /mL) was mixed with 9 times the amount of HIDROX® solution or HT solution.
- the final concentrations of HIDROX® and HT in the mixture were 0.45-11.25 mg/mL and 0.05-0.90 mg/mL, respectively.
- PBS was mixed with the viral solution. These mixtures were placed at 25°C for 5 min-24 hr and then inoculated into cells, and a tenfold serial dilution was performed. After incubation for 3 days, a cytopathic effect caused by inoculated SARS-CoV-2 was observed and the viral titer (logw TCID 50 /mL) was calculated using the Behrens-Karber method (Karber, G., Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakoi. 1931,162, 480-483; doi:10.1007/BF01863914).
- the detection limits for viral titers in each test group were determined based on the cytotoxic concentration of each test solution. The detection limit was set higher in the group treated with a solution of higher cytotoxicity. PBS, 0.45 mg/mL HIDROX®, and 0.05 mg/mL HT solutions did not show any cytotoxicity, and the detection limit of the viral titer in the groups treated by these solutions was set to 1.25 logio TCID 50 /mL, according to the viral titer calculation. In contrast, >0.90 mg/mL HIDROX® and 0.90 mg/mL HT solutions demonstrated cytotoxicity.
- the detection limits in the groups treated with 0.90, 4.50, 5.63 mg/mL HIDROX®, and 0.90 mg/mL HT solutions were set to 2.25 logio TCID 5 o/mL and the detection limit in the group treated by 11.25 mg/mL HIDROX® solution was set to 3.25 logio TCID 50 /mL, respectively.
- FIG. 3, panels A and B show the time- and concentration-dependent virucidal activities of HIDROX® against SARS-CoV-2.
- SARS-CoV-2 was mixed with HIDROX® such that the final concentrations of HIDROX® in each mixture were 0.45, 0.90, and 4.50 mg/mL (FIG. 1, panel A) or 5.63 and 11.25 mg/mL (FIG, 1, panel B).
- PBS was mixed with the viral suspension. The mixtures were incubated at 25 °C for 0.5-24 h (Panel A) or 5 min (Panel B) and then the viral titers were evaluated.
- HIDROX® solutions clearly showed time- and concentration-dependent SARS-CoV-2-inactivating activity.
- the 4.50 mg/mL of HIDROX® solution inactivated 99.68% of virus (2.50 logio TCID 50 /mL reduction of viral titer) in 0.5 hr reaction time.
- the 0.90 mg/mL and 0.45 mg/mL of HIDROX® solutions inactivated 98.53% and 90.00% of virus (1.83 logio TCID 50 /mL and 1.00 logio TCID 50 /mL reduction) in 1.0 hr reaction time, respectively (FIG. 3, panel A).
- Example 3 Time-dependent virucidal activity of HIDROX® solution against variant SARS-CoV-2 strains.
- HIDROX® time-dependent virucidal activity of HIDROX® solution against four variant SARS- CoV-2 strains were determined according to the experimental protocol depicted in FIG. 4.
- HIDROX® was found to inactivate all four different SARS-CoV-2 variants.
- the viral titers in the HIDROX® groups were below the detection limit.
- Example 4 Comparison of virucidal activity of HIDROX® solution and HT solution against SARS-CoV-2.
- FIG. 6, panel A depicts the experimental protocol for evaluating the comparative virucidal activities of HIDROX® and HT against SARS-CoV-2.
- SARS-CoV-2 solutions (7.25 logw TCID 50 /mL) were mixed with 9 times the amount of HIDROX® solution or HT solution and incubated at 25 °C for 3 or 24 hr.
- the final concentration of HIDROX® in the mixture was 0.90 mg/mL; the final concentration of HT in the mixtures were 0.90 mg/mL and 0.05 mg/mL.
- PBS was mixed with the viral suspension as the diluent control. Following the incubations at 25 °C for 3 or 24 hr, the mixtures were inoculated to cells and incubated for 3 days. At this point, a cytopathic caused by inoculated SARS-CoV-2 was observed and the viral titers (logic TCID 50 /mL) in each group were calculated using the Behrens-Karber method. The detection limit for the viral titer in each test group was determined based on the cytotoxic concentration of each test solution.
- FIG. 6, panel B shows the results of the experiment depicted in panel A.
- Example 5 Virucidal activity of HIDROX® in SARS-CoV-2 infected cells at various concentrations.
- FIG. 7 panel A shows an experimental protocol for examining the direct virucidal activity of HIDROX® against SARS-CoV-2 at various concentrations (6.25 - 100 mg/ml).
- FIG. 7, panel B shows the virucidal activity of HIDROX® at various concentrations in accordance with the schematic diagram in FIG. 7.
- Example 6 Inhibitory effect of HIDROX® on SARS-CoV-2 proliferation.
- FIG. 8 shows an experimental protocol for evaluating the inhibitory effect of HIDROX® (pH 7.4) on virus proliferation in host cells.
- FIG. 9 shows the results of the experiment described in FIG. 8.
- Example 7 Virucidal activity of HIDROX® in SARS-CoV-2 infected cells at low concentrations
- FIG. 10 shows an experimental protocol for examining the direct virucidal activity of HIDROX® against SARS-CoV-2 at low concentrations (0.5 - 5.0 mg/ml).
- FIG. 11 shows the results of the experiment described in FIG. 10.
- Example 8 Cytotoxicity of HT compared to HIDROX®.
- FIG. 12 shows the cytotoxicity of HT (0 - 50 pg/ml) compared to HIDROX® (0 - 250 pg/ml).
- Example 9 Comparison of the virucidal activities of HIDROX® and HT against SARS-CoV-2.
- FIG. 13 panel A shows an experimental protocol for comparing the virucidal activities of HIDROX® and HT against SARS-CoV-2 at 1.0 mg/ml and 0.05 mg/ml.
- FIG. 13, panel B shows the result of the experiment described in panel A.
- Example 10 Time- and concentration-dependent virucidal activity of HIDROX®-containing cream against SARS-CoV-2.
- HIDROX®-containing cream which is assumed to be used for topical application like a hand cream, against SARS-CoV-2 was evaluated. Briefly, 20mg of test cream was applied on 2.25 cm 2 (1.5 cm x 1.5 cm) of polyethylene terephthalate film (AS ONE Co., Ltd., Osaka, Japan). The lid of 12 well plate (Nunc, Rochester, NY, USA) was turned over and 5.25 logio TCID50/60 ml of SARS-CoV-2 solution was dropped to the inside of well-lid. The viral solution was covered by the cream-coated film. In this setting, the cream was in contact with the viral solution.
- the 12 well plate was placed for 10 min-6 hr at 25°C. After the predetermined reaction times, the viral solution was recovered. This viral solution was inoculated into cells and tenfold serial dilutions were prepared. After incubation for 1 hr at 37 °C, the cell culture medium containing virus was removed and new VGM was added. After incubation for 3 days at 37°C, the viral titer (logic TCID 50 /mL) was calculated.
- HIDROX®-containing cream Upon application of 20 mg of HIDROX®-containing cream to 2.25 cm 2 of film clearly showed time- and concentration-dependent SARS-CoV-2-inactivating activity (FIG. 14).
- the 10% and 5% HIDROX®-containing creams inactivated 94.38% and 79.47% of virus (1.25 logic TCID 50 /mL and 0.69 logic TCID 50 /mL reduction of viral titer) in 10 min reaction time, respectively.
- the 2% HIDROX®-containing cream also inactivated 94.38% of virus (1.25 logio TCID 50 /mL reduction of viral titer) in 30 min reaction time (FIG. 14).
- Example 11 Impact of HIDROX® and HT on SARS-CoV-2 structural proteins.
- HIDROX®- and HT-treated viruses also showed these two bands in 0 hr (no reaction time), the intensity of these bands became weaker and the other bands or ladder with >250 kDa was appeared in 24 hr reaction time (FIG. 15, panel A, left and middle).
- Example 12 Interaction of HIDROX® or HT with carbohydrate chains expressed on S proteins.
- S protein of SARS-CoV-2 is highly glycosylated by post- translational modification.
- the interaction of HIDROX® and HT with carbohydrate chains attached to S protein was evaluated.
- the recombinant S protein SI subunit, RBD, and S2 subunit which were non-treated (glycosylated) or treated by glycosidase (deglycosylated) beforehand were mixed with PBS, HIDROX®, or HT solution. After 24 hr reaction time WB was performed. In the WB to detect SI subunit, the specific bands with ⁇ 150 kDa and ⁇ 75 kDa were detected in glycosylated- and deglycosylated-proteins treated by PBS, respectively.
- Example 13 Impact of HIDROX® and HT on SARS-CoV-2 genome.
- HIDROX® and HT were extracted from PBS-, HIDROX®-, and HT-treated viruses and real-time RT-PCR was performed. While the Ct values were similar among all treatment groups in 0 hr (no reaction time), these values were 3.19 and 2.63 higher in HIDROX® and HT groups than that of PBS group in 24 hr reaction time, respectively. This increase of Ct values meant that the amount of viral RNA was 9.13 and 6.17 times lower in HIDROX® and HT groups than that of PBS group, respectively (FIG. 17). This result indicates that HIDROX® and HT disrupt viral genome.
- Example 14 Cytotoxicity of HT compared to HIDROX® in MDCK cells.
- FIG. 18 shows the cytotoxicity of HT (0 - 500 ⁇ g/ml) compared to HIDROX® (0 - 500 ⁇ g/ml) in MDCK cells, the host cells for influenza (H1N1) in the experiment described in FIG. 19.
- Example 15 Virucidal activity of HIDROX® against influenza- infected MDCK cells.
- FIG. 19 Panel A shows an experimental protocol for evaluating the virucidal activity of HIDROX® against influenza-infected MDCK cells at various different concentrations and incubation periods.
- FIG. 19, panel B shows the result of the experiment described in panel A.
- Example 16 Analysis of the OLIVENOLTM dietary supplement.
- OLIVENOLTM is a dietary supplement.
- the amount of phenolic compounds in the OLIVENOLTM and two different batches of vegetation water from olive oil processing (CR43 and CR21) are shown in Table 5.
- Gas chromatographic profiles in the time range 15-25 min, generally attributable to simple phenols, have shown that OLIVENOLTM composition is qualitatively similar to that of the phenolic fraction of extravirgin olive oil (FIG. 20), notwithstanding the quantitative contents being different.
- the concentrations of tyrosol and hydroxytyrosol in OLIVENOLTM are about 50 and 30-fold higher than that present in the extra- virgin olive oil studied.
- the transformed OVWs can be subjected to centrifugation, filtration and pasteurization processes.
- the phenolic composition of the OLIVENOLTM was compared to that of the VW CR43 used for its production. After the treatments, no significant qualitative (FIG. 20) or quantitative (Table 5) differences were observed in the aqueous phase compositions from both samples.
- the increase of the OLIVENOLTM dry weight can be attributed to the presence of vegetable glycerin and vegetable gum used as emulsifiers and sweeteners in the final product.
- the total phenolic content was almost the same (Table 5).
- Example 17 Conversion of vegetation waters into hydroxytyrosol-rich mixtures by acidic hydrolysis.
- the studied OVW was obtained from depitted olives so explaining the lower initial tyrosol amount, being this simple phenol present in the seed and in the stone at levels comparable to those revealed in the pulp.
- the total phenol amount in the sample incubated in the presence of citric acid indicates that the OVWs are stable in acidic environment.
- the presence of citric acid as demonstrated for the ascorbic acid, can contribute to keep the phenols concentration constant avoiding the quinones accumulation and the formation of insoluble polymers, due to the direct oxidation by molecular oxygen.
- these polymeric phenolic compounds give the sludge characterized by a recalcitrant brownish black color.
- Table 7 Compounds identified in the aqueous phase of vegetation water treated and not treated with citric acid (1.5%). The hints of the identification for each compound have a probability higher than 70%.
- Example 18 Inhibitory effects of Olivenol plus® Essence Liquid and HIDROX® on suppression of SARS-CoV-2 proliferation.
- FIG. 22 panel A, shows an experimental protocol for evaluating inhibitory effects of Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 22, panel B shows the results of the experiment in FIG. 22, panel A.
- FIG. 23 panel A shows an experimental protocol for evaluating inhibitory effects of HIDROX® on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 23, panel B shows the results of the experiment in FIG. 23, panel A.
- Example 19 Antiviral activity of cells pre-treated with Olivenol plus® Essence Liquid and HIDROX®.
- FIG. 24 panel A shows an experimental protocol for evaluating antiviral activity of cells pre-treated with Olivenol plus® Essence Liquid. Suppression of SARS-CoV-2 proliferation in cells was determined.
- FIG. 24, panel B shows the results of the experiment in FIG. 24, panel A.
- FIG. 25 shows an experimental protocol for evaluating antiviral activity of cells pre-treated with HIDROX®. Suppression of SARS-CoV-2 proliferation in the cells was determined.
- FIG. 25, panel B shows the results of the experiment in FIG. 26, panel A.
- Example 20 Virucidal activity of Olivenol plus® Essence Liquid and HIDROX® on suppression of SARS-CoV-2 proliferation.
- FIG. 26 panel A shows an experimental protocol for evaluating direct virucidal activity of Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 26, panel B shows the results of the experiment in FIG. 26, panel A.
- FIG. 27, panel A shows an experimental protocol for evaluating direct virucidal activity of HIDROX® on suppression of SARS-CoV-2 proliferation in cells.
- FIG. 27, panel B shows the results of the experiment in FIG. 27, panel A.
- Example 21 Effects of acidic pH on HIDROX®’s virucidal activity in suppressing SARS-CoV-2 proliferation.
- FIG. 28 shows an experimental protocol for evaluating the effects of acidic pH on HIDROX®’ s virucidal activity in suppressing SARS-CoV-2 proliferation in cells.
- FIG. 28, panel B shows the results of the experiment in FIG. 28, panel A.
- Example 22 Effects of HIDROX® in suppressing proliferation of the Delta variant of SARS-CoV-2.
- VeroE6/TMPRSS2 cells were cultured in the growth medium: Dulbecco’s Modified Eagle’s medium (DMEM; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% fetal bovine serum, 2 mM L-glutamine (Wako Pure Chemical Industries, Ltd., Osaka, Japan), 0.15% NaHCO3 (Wako Pure Chemical Industries, Ltd.), 2 pg/ml amphotericin B (Bristol-Myers Squibb Co., NY, USA), and 100 ⁇ g/mL kanamycin (Meiji Seika Pharma Co., Ltd., Tokyo, Japan).
- VeroE6/TMPRSS2 cells were cultured in viral growth medium (VGM) composed of DMEM supplemented with 1% fetal bovine serum, 2 mM L-glutamine, 0.15% NaHCO3, 2 ⁇ g/mL amphotericin B, and 100 ⁇ g/mL kanamycin.
- VGM viral growth medium
- the viral titer of the stock solution (VGM) ccontaini containing SARS-CoV-2) was ⁇ 6.9 loglO 50% tissue culture infective dose (TCID50)/mL.
- mL of phosphate-buffered saline (PBS), and a centrifugation (850 x g, 10 min) was performed.
- the aqueous layer collected was stored at -30°C as the stock of 100 mg/mL HIDROX solution.
- the 1.0 mg/mL of HIDROX solution was prepared by dilution of the stock solutions with PBS. PBS was used as a control solution.
- Viral solution (VGM containing Delta variant of SARS-CoV-2) was mixed with nine volumes of 1.0 mg/mL of HIDROX solution. The final concentrations of HIDROX in the mixture was 0.9 mg/mL.
- PBS was mixed with the viral solution. The mixtures were incubated at 25 °C for 3 or 24 h and then inoculated into the cells, and a tenfold serial dilution was performed.
- the viral titer (loglO TCID50/mL) was calculated using the Behrens-Karber method.
- the detection limit of the viral titer in each test solution group was determined based on the cytotoxicity of each test solution.
- the detection limit of the viral titer in the group treated by PBS and HIDROX solution was set to 1.25 and 2.25 loglO TCID50/mL, respectively.
- FIG. 29, panel A shows the experimental protocol for evaluating the effects of HIDROX on the proliferation of the Delta variant of SARS-CoV-2 in cells.
- FIG. 29, panel B shows the results of the experiment in FIG. 29, panel A.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An olive component composition with anti-viral activity is disclosed. The olive component composition can be used to prevent, treat, or ameliorate symptoms of, viral infection.
Description
ANTIVIRAL OLIVE EXTRACT COMPOSITIONS AND METHODS
[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 63/122,893, filed on December 8, 2020, and U.S. Patent Application Serial No. 17/326,146, filed on May 20, 2021, the contents of which are expressly incorporated herein by reference.
FIELD
[0002] This application generally relates to anti-viral compositions and, in particular, to olive extracts with anti-viral effect and method of use thereof.
BACKGROUND
[0003] Viral infections, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, remain a serious problem. In addition to the existing measures like vaccination, medication, and inactivation of environmental viruses using chemical disinfectants, there is an increasing demand for the development of auxiliary approaches for the preventions of viral infection and aggravation of symptoms.
[0004] The present application addresses this demand by providing natural-derived compositions as supplemental agents for protection from pathogenic viruses, such as SARS- CoV-2.
SUMMARY
[0005] One aspect of the present application relates to a method for preventing, treating, or ameliorating symptoms, of a viral infection in a subject. The method comprises the step of administering to the subject an effective amount of an olive component composition, wherein the olive component composition comprises one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10- hydroxyoleuropein, and 10-hydroxy ligstroside; vanillic acid, 3-hydroxy, 4- metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid,
caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alphatocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, and lycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof.
[0006] Another aspect of the present application relates to a method for preventing or reducing surface transmission of a virus. The method comprises the step of applying an effective amount of an olive component composition to a surface for a period of time to inactivate the virus on the surface, wherein the olive component composition comprises one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, such as oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3- hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alpha-tocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, and lycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof
[0007] Another aspect of the present application relates to an antiviral composition. The composition comprises an olive component composition, wherein the olive component composition comprises: (1) one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxyoleuropein, and 10- hydroxyligstroside; vanillic acid, 3-hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy- benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA- EDA, lignanes, flavonoids, elenolic acid, alpha-tocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, and lycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof, (2) propanoic acid, and optionally (3) no syringic acid or syringic acid in an amount of less than 0.01 mg/ml.
[0008] Another aspect of the present application relates to an antiviral composition formulated for inhalation. The antiviral composition comprises an olive component composition, wherein the olive component composition comprises: one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10- hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3-hydroxy, 4-
metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alphatocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, and lycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof, wherein the antiviral composition is formulated in an aerosol for inhalation.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1 is a schematic illustration of an exemplary process for preparing a hydroxytyrosol (HT)-rich aqueous olive pulp extract (HIDROX®).
[00010] FIG. 2, panel A is a schematic illustration of an experimental protocol for evaluating the time- and concentration-dependent virucidal activity of HIDROX® against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
[00011] FIG. 3 shows the time- and concentration-dependent virucidal activity of HIDROX® against SARS-CoV-2. In the experiments depicted in FIG. 3, SARS-CoV-2 was mixed with HIDROX®. The final concentrations of HIDROX® in the mixture were 0.45, 0.90, and 4.50 mg/mL (FIG. 3, panel A) or 5.63 and 11.25 mg/mL (FIG, 3, panel B). As a diluent control, PBS was mixed with the viral suspension. The mixtures were incubated at 25 °C for 0.5-24 h (Panel A) or 5 min (Panel B) after which the viral titers were evaluated. The detection limits for the viral titers are 1.25 logw at a 50% tissue culture infective dose (TCID50)/mL in the PBS and HIDROX® (0.45 mg/mL) groups, 2.25 logio TCID50/mL in the HIDROX® (0.9, 4.50, and 5.63 mg/mL) groups, and 3.25 log10 TCID50/mL in the HIDROX® (11.25 mg/mL) group. Results are indicated as mean ± SD (n = 3-4 per group). Student’s /-test was performed to evaluate the statistically significant difference between the PBS and HIDROX® groups; * p < 0.05; ** p < 0.01; *** p < 0.001.
[00012] FIG. 4 shows an experimental protocol for evaluating the time-dependent virucidal activity of HIDROX® against four SARS-CoV-2 variant strains, namely the UK variant, the Brazilian variant the South African variant and the Delta variant.
[0010] FIG. 5 shows the time-dependent virucidal activity of HIDROX® against the four SARS-CoV variants according to the experimental protocol depicted in FIG. 4. Student’s /-test was performed to evaluate the statistically significant difference between the PBS group and each test group; ** p < 0.01; *** p < 0.001.
[0011] FIG. 6, panel A depicts an experimental protocol for evaluating the comparative virucidal activities of HIDROX® and HT against SARS-CoV-2. In FIG. 6, HIDROX® and HT were mixed with SARS-CoV-2 at 0.90 mg/ml, inoculated to cells and
incubated at 25 °C for 3 or 24 hr. The final concentration of HIDROX® in the mixture was 0.90 mg/mL; the final concentration of HT in the mixtures were 0.90 mg/mL and 0.05. PBS was mixed with the viral suspension as the diluent control. Following the incubation period, viral titers were determined. FIG. 6, panel B shows the results of the experiment depicted in FIG. 6, panel A. In panel B, the detection limits of viral titer are 1.25 logio 50% tissue culture infective dose (TCIDso)/mL in the PBS and HT (0.05 mg/mL) groups and 2.25 logio TCID50/mL in the HIDROX® (0.9 mg/mL) and HT (0.90 mg/mL) groups. Results are indicated as mean ± SD (n = 4 per group). Student’s /-test was performed to evaluate the statistically significant difference between the PBS group and each test group; * p < 0.05;
*** p < 0.001
[0012] FIG. 7, panel A shows an experimental protocol for examining the direct virucidal activity of HIDROX® against SARS-CoV-2 at various concentrations (6.25 - 100 mg/ml). FIG. 7, panel B shows the virucidal activity of HIDROX® at various concentrations in accordance with the schematic diagram in FIG. 7.
[0013] FIG. 8 shows an experimental protocol for evaluating the inhibitory effect of HIDROX® (pH 7.4) on virus proliferation in host cells.
[0014] FIG. 9 shows the results of the experiment described in FIG. 8.
[0015] FIG. 10 shows an experimental protocol for examining the direct virucidal activity of HIDROX® against SARS-CoV-2 at low concentrations (0.5 - 5.0 mg/ml).
[0016] FIG. 11 shows the results of the experiment described in FIG. 10.
[0017] FIG. 12 shows the cytotoxicity of HT (0 - 50 pg/ml) compared to
HIDROX® (0 - 250 pg/ml).
[0018] FIG. 13, panel A shows an experimental protocol for comparing the virucidal activities of HIDROX® and HT against SARS-CoV-2 at 1.0 mg/ml and 0.05 mg/ml. FIG. 13, panel B shows the result of the experiment described in panel A.
[0019] FIG. 14 shows the time- and concentration-dependent virucidal activity of HIDROX®-containing cream against SARS-CoV-2. SARS-CoV-2 was covered by 0%, 2%, 5%, and 10% HIDROX®-containing cream-coated films and incubated for 10 min-6 h at 25 °C. After the predetermined reaction times, the viral solutions were recovered and the viral titers were determined. The detection limit of the viral titer is 1.25 logio 50% tissue culture infective dose (TCIDso)/mL in all groups. Results are indicated as mean ± SD (n= 4-8 per group). Student’s /-test was performed to evaluate the statistically significant differences between the 0% HIDROX® group and other groups; * p < 0.05; ** p < 0.01; *** p < 0.001.
[0020| FIG. 15 shows the impact of HIDROX® and HT on SARS-CoV-2 proteins. As shown in FIG. 15, panel A, SARS-CoV-2 was mixed with HIDROX® or HT. The final concentrations of HIDROX® and HT in each mixture was 0.90 mg/mL. PBS was mixed with the SARS-CoV-2 as a diluent control. The mixtures were incubated at 25 °C for 0 (no reaction time) or 24 h, and then Western blotting was performed. In FIG. 15, panel A, the images on the left, middle, and right show the results of Western blotting to detect S protein SI subunit, S protein S2 subunit, and N protein, respectively. In FIG. 15, panel B, the recombinant S protein RBD or N protein was mixed with PBS, HIDROX®, or HT. The final concentration of HIDROX® and HT in each mixture was 0.90 mg/mL. The final concentration of recombinant viral proteins in each mixture was approximately 10 μ. g/mL The mixtures were incubated at 25 °C for 0 (no reaction time) or 24 h and then Western blotting was performed. The images on the left and right show the results of Western blotting to detect S protein RBD and N protein, respectively.
[0021] FIG. 16 shows the impact of HIDROX® or HT on carbohydrate chains expressed on the S protein. In this experiment, glycosylated and deglycosylated forms of recombinant S protein SI subunit, RBD, and S2 subunit were mixed with PBS, HIDROX®, or HT. The final concentration of HIDROX® and HT in each mixture was 0.90 mg/mL. The final concentration of recombinant S proteins in the mixtures was approximately 10 .μg/mL The mixtures were incubated at 25 °C for 24 h and then Western blotting was performed. The images on the left, middle, and right show the glycosylated and unglycosylated forms of the SI subunit, RBD, and S2 subunit, respectively.
[0022] FIG. 17 shows the impact of HIDROX® and HT on SARS-CoV-2 genome. In this experiment, SARS-CoV-2 was mixed with HIDROX® or HT at a concentration of 0.90 mg/mL. As a diluent control, PBS was mixed with SARS-CoV-2. The mixtures were incubated at 25 °C for 0 (no reaction time) or 24 h. Then real-time RT-PCR was performed and Ct values were determined. The results are indicated as mean ± SD (n= 4 per group). Student’s /-test was performed to evaluate the statistically significant differences between the PBS group and each test solution group; ** p < 0.01; *** p < 0.001.
[0023] FIG. 18 shows the cytotoxicity of HT (0 - 500 pg/ml) compared to HIDROX® (0 - 500 pg/ml) in MDCK cells, the host cells for influenza (H1N1) in the experiment described in FIG. 19.
[0024] FIG. 19, panel A shows an experimental protocol for evaluating the virucidal activity of HIDROX® against influenza-infected MDCK cells at various different
concentrations and incubation periods. FIG. 19, panel B shows the result of the experiment described in panel A.
[0025] FIG. 20 shows GC chromatographic profiles of (A) OLIVENOL™ (in column 9.0 pg), vegetation waters (B) CR43 (10.0 pg) and (C) CR21 (8.0 pg), and (d) polar fraction from 100 ml of Moraiolo extra-virgin olive oil (17.8 pg). Peaks: 1, tyrosol; 2, vanillic acid; 3, hydroxytyrosol (i.e. HT); 4, 3,4-dihydroxybenzoic acid; 5, citric acid; 6, syringic acid; 7, gallic acid.
[0026] FIG. 21 shows GC chromatographic profiles of (A) not treated OVW at time O (in column 12.0 pg), (B) not treated OVW after 6 months (12.0 pg) and (C) treated OVW after 6 months (10.0 pg). Peaks: 1, tyrosol; 2, vanillic acid; 3, hydroxy tyrosol; 4, 3,4- dihydroxybenzoic acid; 5, citric acid; 6, syringic acid; 7, gallic acid; 8, caffeic acid; 9, 3- hydroxy, 4-metoxy-phenylacetic acid; 10, gentisic acid.
[0027] FIG. 22, panel A shows an experimental protocol for evaluating inhibitory effects of Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells. FIG. 22, panel B shows the results of the experiment in FIG. 22, panel A.
[0028] FIG. 23, panel A shows an experimental protocol for evaluating inhibitory effects of HIDROX® on suppression of SARS-CoV-2 proliferation in cells. FIG. 23, panel B shows the results of the experiment in FIG. 23, panel A.
[0029] FIG. 24 shows an experimental protocol for evaluating antiviral activity of cells pre-treated with Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells. FIG. 24, panel B shows the results of the experiment in FIG. 24, panel A.
[0030] FIG. 25 shows an experimental protocol for evaluating antiviral activity of cells pre-treated with HIDROX® on suppression of SARS-CoV-2 proliferation in cells. FIG. 25, panel B shows the results of the experiment in FIG. 25, panel A.
[0031] FIG. 26, panel A shows an experimental protocol for evaluating direct virucidal activity of Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells. FIG. 26, panel B shows the results of the experiment in FIG. 26, panel A.
[0032] FIG. 27, panel A shows an experimental protocol for evaluating direct virucidal activity of HIDROX® on suppression of SARS-CoV-2 proliferation in cells. FIG. 27, panel B shows the results of the experiment in FIG. 27, panel A.
[0033] FIG. 28, panel A shows an experimental protocol for evaluating the effects of acidic pH on HIDROX®’s virucidal activity in suppressing SARS-CoV-2 proliferation in cells. FIG. 28, panel B shows the results of the experiment in FIG. 28, panel A.
[0034] FIG. 29, panel A shows an experimental protocol for evaluating the effects of HIDROX® in suppressing the proliferation of the Delta variant of SARS-CoV-2 in cells. FIG. 29, panel B shows the results of the experiment in FIG. 29, panel A.
DETAILED DESCRIPTION
[0035] The disclosure and accompanying drawings will now be discussed to enable one skilled in the art to practice the invention described herein. The skilled artisan will understand, however, that the embodiments described below can be practiced without employing every specific detail, or that they can be used for purposes other than those described herein. Indeed, they can be modified and can be used in conjunction with products and techniques known to those of skill in the art considering the present disclosure. The drawings and descriptions are intended to be exemplary of various aspects of the disclosure and are not intended to narrow the scope of the appended claims. Furthermore, it will be appreciated that the drawings may show aspects of the disclosure in isolation and the elements in one figure may be used in conjunction with elements shown in other figures.
[0036] It will be appreciated that reference throughout this specification to aspects, features, advantages, or similar language does not imply that all the aspects and advantages may be realized with the present disclosure or realized are in any single embodiment of the disclosure. Rather, language referring to the aspects and advantages should be understood to mean that a specific aspect, feature, advantage, or characteristic described in connection with an embodiment is included in at least one embodiment of the present disclosure. Thus, discussion of the aspects and advantages, and similar language, throughout this specification may, but do not necessarily, refer to the same embodiment.
[0037] The described aspects, features, advantages, and characteristics of the disclosure may be combined in any suitable manner in one or more further embodiments. Furthermore, one skilled in the relevant art will recognize that the embodiments may be practiced without one or more of the specific aspects or advantages of a particular embodiment. In other instances, additional aspects, features, and advantages may be recognized and claimed in certain embodiments that may not be present in all embodiments of the disclosure.
[0038] While several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.
I. Definitions
[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. One of skill in the art will recognize many techniques and materials similar or equivalent to those described here, which could be used in the practice of the aspects and embodiments of the present disclosure. The described aspects and embodiments of the application are not limited to the methods and materials described.
[0040] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.
[0041] All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.
[0042] The terms “a”, “an,” or “the” as used in the specification and claims, unless clearly indicated to the contrary, should be understood to mean “at least one” or “one or more,” unless the content clearly dictates otherwise.
[0043] The phrase “and/or,” as used herein in the specification and claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
[0044] It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
[0045] In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of’ and “consisting essentially of’ shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03. Further, if the disclosure describes “a composition comprising A and B”, the disclosure also contemplates the alternative embodiments “a composition consisting of A and B” and “a composition consisting essentially of A and B”.
[0046] Where ranges are given, endpoints are included. Further, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific subrange within the stated ranges in different embodiments of the invention, or any subrange defined by any pair of integers within a stated range, unless the context clearly dictates otherwise.
[0047] In addition, it is to be understood that any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the compositions of the invention (e.g., any nucleic acid or protein encoded thereby; any method of production; any method of use; etc.) can be excluded from any one or more claims, for any reason, whether or not related to the existence of prior art.
[0048] As used herein, the phrases “administered in combination” or "combined administration" means that two or more agents are administered to a subject at the same time or within an interval such that there may be an overlap of an effect of each agent on the patient. In some embodiments, they are administered within about two weeks, one week, 2-5 days, one week, 60 min, 30 min, 15 min, 10 min, 5 min, or 1 min of one another. In some embodiments, the administrations of the agents are spaced sufficiently closely together such that a combinatorial (e.g., a synergistic) effect is achieved.
[0049] As used herein, the term "approximately" or "about," as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
[0050] The term "control individual" is an individual who is not afflicted with the same virus as the individual being treated, who is about the same age as the individual being treated (to ensure that the stages of the disease in the treated individual and the control individual(s) are comparable). The individual (also referred to as "patient" or "subject") being treated may be a fetus, infant, child, adolescent, or adult human.
[0051] The phrases "effective amount", “therapeutically effective amount” and "pharmacologically effective amount" are used interchangeably with reference to an amount of an agent that is sufficient to effect beneficial or desired results, for example, clinical results, and, as such, an "effective amount" depends upon the context in which it is being applied. For example, in the context of administering an antiviral composition for a SARS- CoV-2 infection, an effective amount refers to an amount sufficient to provide antiviral activity against SARS-CoV-2, as compared to responses (or lack thereof) obtained without administration of the antiviral composition.
[0052] The terms, "improve", "increase," "reduce", “ameliorate,” as used in this context, indicate values or parameters relative to a baseline measurement, such as a measurement in the same individual prior to initiation of the treatment described herein, or a measurement in a control individual (or multiple control individuals) in the absence of the treatment
[0053] The phrase "pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio when administered to an animal or a human, as appropriate.
[0054] The term “pharmaceutically acceptable carrier” refers to pharmaceutically- acceptable materials, compositions or vehicles, including any and all solvents, solubilizers, fillers, diluents, stabilizers, surfactants, binders, absorbents, bases, buffering agents, excipients, lubricants, controlled release vehicles, diluents, emulsifying agents, encapsulating materials, humectants, lubricants, gels, dispersion media, coatings, antibacterial or antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such carriers and agents for pharmaceutically active substances is well-known in the art.
[0055] As used herein, the term "preventing" refers to partially or completely delaying onset of a viral infection, such as a SARS-CoV-2 infection, disease, disorder and/or condition thereof; partially or completely delaying onset of one or more symptoms, features, or clinical manifestations of a viral infection, disease, disorder, and/or condition thereof; partially or completely delaying onset of one or more symptoms, features, or manifestations of a viral infection, disorder, and/or condition thereof; partially or completely delaying progression from viral infection, disease, disorder and/or condition thereof; and/or decreasing the risk of developing pathology associated with viral infection, disease, disorder, and/or condition thereof.
[0056] As used herein, "SARS-CoV-2" refers to betacoronavirus believed to be of lineage B (sarbecovirus). SARS-CoV-2 was first identified in Wuhan, Hubei province, China, in late 2019. As used herein, the term “SARS-CoV-2” refers to both the “SARS-CoV-2 original strain” and variants of the SARS-CoV-2 original strain.
[0057] As used herein, the phrase a “variant of SARS-CoV-2” and “SARS-CoV-2 variant” are used interchangeably with reference to SARS-CoV-2 strains that differ from original or progenitor SARS-CoV-2 strains by one or more nucleotides in the viral genome.
Variants of the SARS-CoV-2 original strain may be further divided into subgroups of variants, such as Alpha variants, Beta variants, Delta variants, Delta plus variants, omicron variants and the like, which have accumulated enough mutations to represent separate branches on the family tree.
[0058] As used herein, the term “SARS-CoV-2 spike protein,” refers to the spike protein of SARS-CoV-2, which plays a key role in the receptor recognition and cell membrane fusion process.
[0059] As used herein, the term “SARS-CoV-2 SI protein,” refers to the SI subunit of the SARS-CoV-2 spike protein.
[0060] As used herein, the term “subject” refers to any human or non-human mammal to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. In some embodiments, "subject" refers to a human or non-human mammal at any stage of development. In certain embodiments, the non-human mammal is, for example, a primate, monkey, rodent, mouse, rat, rabbit, monkey, dog, cat, sheep, pig, cattle, or sheep. In some embodiments, the animal is a transgenic or genetically-engineered mammal.
[0061] As used herein, the term "substantially" refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% in relation to a reference property of interest). One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term "substantially" is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0062] The terms "treat" and "treatment" refer to the amelioration of one or more symptoms associated with a coronavirus infection; prevention or delay of the onset of one or more symptoms of a viral infection; and/or lessening of the severity or frequency of one or more symptoms of the infection.
II. Compositions and Formulations
A. Olive component composition
[0063] One aspect of the present application relates to an olive component (OC) composition having anti-viral activity. As used herein, the term “olive component (OC)” refers to chemical compounds, complexes or materials that are present in olives, the fruit
of Olea europaea, or in products derived from olives, such as olive oil vegetation waters and the acidic hydrolysis products thereof. An OC may be obtained from a non-olive fruit or plant, or by chemical synthesis.
[0064] In some embodiments, the OC composition of the present application comprises one or more polyphenols. Polyphenols are a group of natural products occurring in tissues of all higher plants. Polyphenols are characterized by the presence of large multiples of phenol structural units. The number and characteristics of these phenol structures underly the unique physical, chemical, and biological (e.g., metabolic, toxic, and therapeutic) properties of particular members of the class. Polyphenols may be broadly classified as phenolic acids, flavonoids, stilbenes, and lignans. Of the various plants, the olive (Olea europaea L.) contains a large number of polyphenols. Exemplary polyphenol compounds in olives for use in the OC compositions of the present application include, but are not limited to, hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3-hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alpha-tocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, including glycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof.
[0065] In some embodiments, the OC composition of the present application comprises hydroxytyrosol, and one or more polyphenols selected from the group consisting of tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3- hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alpha-tocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, including glycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof.
[0066] In some embodiments, the OC composition of the present application comprises (1) one or more polyphenols selected from the group consisting of tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA- EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10- hydroxyoleuropein, and 10-hydroxyligstroside; vanillic acid, 3-hydroxy, 4- metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid,
caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alphatocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, including glycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof, and (2) hydroxytyrosol in an amount less than 0.5 wt%, 0.2 wt%, 0.1 wt%, 0.05 wt%, 0.02 wt%, 0.01 wt%, 0.005 wt%, 0.002 wt%, 0.001 wt%, 0.0005 wt%, 0.0002 wt%, or 0.0001 wt%.
[0067] In some embodiments, the OC composition of the present application further comprises one or more non-phenolic compounds. Exemplary non-phenolic compounds in olives for use in the composition of the present application include, but are not limited to, D-fructose, glucofuranoside, glucopyranoside, dihydroxyacetone, malic acid, trihydroxybutyric acid, glucitol, glycerol, propanoic acid, xylonic acid, xylulose, xylitol, arabinose, ribose, deoxyribose, galactopyranoside, ketogluconic acid and galactofuranose.
[0068] In some embodiments, the OC composition of the present application comprises one or more compounds selected from the group consisting of hydroxytyrosol, tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid, syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, lycopene, apigenin, rutin, [3-carotene, 9-hexadecenoic acid, cholestan-3-ol, 2- methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3-hydroxy, 4-metoxy- phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1-heptatriacotanol, apigenine, azulene and astaxanthin.
[0069] In some embodiments, the OC composition of the present application comprises (1) hydroxytyrosol, (2) propanoic acid, and (3) one or more compounds selected from the group consisting of tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid, syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, lycopene, apigenin, rutin, [3-carotene, 9- hexadecenoic acid, cholestan-3-ol, 2-methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3-hydroxy, 4-metoxy-phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1-heptatriacotanol, apigenine, azulene, astaxanthin, D-fructose, glucofuranoside, glucopyranoside, dihydroxy acetone, malic acid, trihydroxybutyric acid, glucitol, glycerol, propanoic acid, xylonic acid, xylulose, xylitol, arabinose, ribose, deoxyribose, galactopyranoside, ketogluconic acid and galactofuranose.
[0070] In some embodiments, the OC composition of the present application comprises (1) hydroxytyrosol, (2) propanoic acid, and (3) one or more compounds selected from the group consisting of tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid,
syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, lycopene, apigenin, rutin, [3-carotene, 9- hexadecenoic acid, cholestan-3-ol, 2-methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3-hydroxy, 4-metoxy-phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1-heptatriacotanol, apigenine, azulene, astaxanthin, malic acid, trihydroxybutyric acid, glucitol, glycerol, propanoic acid, xylonic acid, xylulose, xylitol, arabinose, ribose, deoxyribose, galactopyranoside, ketogluconic acid and galactofuranose, wherein the OC composition does not comprise D-fructose, glucofuranoside, glucopyranoside and/or dihydroxyacetone, or wherein the OC composition comprises D-fructose, glucofuranoside, glucopyranoside and/or dihydroxy acetone in a total amount of less than 0.1 wt%, 0.01 wt% or 0.001 wt%.
[0071] In some embodiments, the OC composition of the present application comprises (1) hydroxy tyrosol; and (2) one or more compounds selected from the group consisting of tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid, syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, lycopene, beta-carotene, apigenin, rutin, 9-hexadecenoic acid, cholestan-3-ol, 2-methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3- hydroxy, 4-metoxy-phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1- heptatriacotanol, apigenine, azulene and astaxanthin; wherein the OC composition does not comprise beta-catotene and/or lycopene, or wherein the OC composition comprises beta- catotene and/or lycopene in an total amount of less than 1 wt %, 0.1 wt % or 0.01 wt %.
[0072] In some embodiments, the OC composition of the present application comprises (1) hydroxy tyrosol; and (2) one or more compounds selected from the group consisting of tyrosol, oleuropein, vanillic acid, gallic acid, caffeic acid, syringic acid, ferrulic acid, ellagic acid, elenolic acid, oleanolic acid, linoleic acid, oleic acid, luteolin, kaemperol, quercetin, cathechin, apigenin, rutin, lycopene, [3-carotene, 9-hexadecenoic acid, cholestan-3- ol, 2-methylene, 13-heptadecynl-ol, cis-13-eicosenoid acid, decanoic acid, 3-hydroxy, 4- metoxy-phenylacetic acid, 3,4-dihydrooxybenzoic acid, gentisic acid, 1-heptatriacotanol, apigenine, azulene and astaxanthin; wherein the OC composition does not comprise gallic acid, linoleic acid, oleic acid, and/or luteolin, or wherein the OC composition comprises gallic acid, linoleic acid, oleic acid and/or luteolin in a total amount of less than 1 wt %, 0.1 wt % or 0.01 wt %.
[0073] In some embodiments, the OC composition of the present application comprises an aqueous olive pulp extract (AOPE), a concentrated AOPE or dried powder of AOPE.
[0074] In some embodiments, the OC composition of the present application comprises 0.1-50 wt %, 0.1-0.2 wt %, 0.1-0.5 wt %, 0.1-1 wt %, 0.1-2 wt %, 0.1-5 wt%, 0.1- 10 wt %, 0.1-20 wt %, 0.2-0.5 wt%, 0.2-1 wt %, 0.2-2 wt %, 0.2-5 wt%, 0.2-10 wt %, 0.2-20 wt %, 0.2-50 wt%, 0.5-1 wt %, 0.5-2 wt %, 0.5-5 wt%, 0.5-10 wt %, 0.5-20 wt %, 0.5-50 wt%, 1-2 wt %, 1-5 wt%, 1-10 wt %, 1-20 wt %, 1-50 wt%, 2-5 wt%, 2-10 wt %, 2-20 wt %, 2-50 wt%, 5-10 wt %, 5-20 wt %, 5-50 wt%, 10-20 wt %, 10-50 wt% or 20-50 wt% phenolic compounds. In some embodiments, the OC composition of the present application comprises about 0.5 wt%, about 2 wt%, about 3 wt%, about 9 wt% or about 12 wt % phenolic compounds.
[0075] In some embodiments, the phenolic compounds of the above-described OC composition comprise (1) hydroxytyrosol in the range of 10-70 wt%, 10-15 wt%, 10-20 wt%, 10-25 wt%, 10-30 wt%, 10-35 wt%, 10-40 wt%, 10-45 wt%, 10-50 wt%, 10-55 wt%, 10-60 wt%, 10-65 wt%, 15-20 wt%, 15-25 wt%, 15-30 wt%, 15-35 wt%, 15-40 wt%, 15-45 wt%, 15-50 wt%, 15-55 wt%, 15-60 wt%, 15-65 wt%, 15-70 wt%, 20-25 wt%, 20-30 wt%, 20-35 wt%, 20-40 wt%, 20-45 wt%, 20-50 wt%, 20-55 wt%, 20-60 wt%, 20-65 wt%, 20-70 wt%, 25-30 wt%, 25-35 wt%, 25-40 wt%, 25-45 wt%, 25-50 wt%, 25-55 wt%, 25-60 wt%, 25-65 wt%, 25-70 wt%, 30-35 wt%, 30-40 wt%, 30-45 wt%, 30-50 wt%, 30-55 wt%, 30-60 wt%, 30-65 wt%, 30-70 wt%, 35-40 wt%, 35-45 wt%, 35-50 wt%, 35-55 wt%, 35-60 wt%, 35-65 wt%, 35-70 wt%, 40-45 wt%, 40-50 wt%, 40-55 wt%, 40-60 wt%, 40-65 wt%, 40-70 wt%, 45-50 wt%, 45-55 wt%, 45-60 wt%, 45-65 wt%, 45-70 wt%, 50-55 wt%, 50-60 wt%, 50-65 wt%, 50-70 wt%, 55-60 wt%, 55-65 wt%, 55-70 wt%, 60-65 wt%, 60-70 wt% or 65-70 wt% of the phenolic compounds, and/or (2) oleuropein in the range of 1-20 wt%, 1-2 wt%, 1-5 wt%, 1-10 wt%, 1-15 wt%, 2-5 wt%, 2-10 wt%, 2-15 wt%, 2-20 wt%, 5-10 wt%, 5-15 wt%, 5-20 wt%, 10-15 wt%, 10-20 wt% or 15-20 wt% of the phenolic compounds; and (3) tyrosol in the range of 0.03-3 wt%, 0.03-0.1 wt%, 0.03-0.3 wt%, 0.03-1 wt%, 0.1-0.3 wt%, 0.1-1 wt%, 0.1-3 wt%, 0.3-1 wt%, 0.3-3 wt% or 1-3 wt% the phenolic compounds. In some embodiments, phenolic compounds of the above-described OC composition comprise about 35-45 wt% hydroxytyrosol, 5-10 wt% oleuopein and 0.1-0.5 wt% tyrosol.
[0076] In some embodiments, the OC composition of the present application comprises an aqueous olive pulp extract, a concentrated aqueous olive pulp extract, or a dried aqueous olive pulp extract. In some embodiments, the OC composition of the present
application comprises an aqueous olive pulp extract treated with acid hydrolysis. In some embodiment, the OC composition of the present application comprises one or more of the compounds in the amount shown in Table 1.
[0077] Table 1. Components of the OC composition of the present application
[0078] In some embodiment, the OC composition of the present application comprises one or more of the compounds in the amount shown in Table 2.
[0079] Table 2. Composition of the OC composition of the present application
B. Formulation comprising the OC composition
[0080] Another aspect of the present application relates to an anti-viral formulation comprising the OC composition of the present application. In some embodiments, the anti-viral formulation is a nutraceutical. In some embodiments, the antiviral formulation is formulated as a moisturizer lotion or cream for topical application. In some embodiments, the anti-viral formulation is formulated as a dietary supplement. In some
embodiments, the anti-viral formulation is formulated as an aerosol for inhalation. In some embodiments, the anti-viral formulation is a pharmaceutical composition comprising the OC composition of the present application and a pharmaceutically acceptable carrier.
[0081] In some embodiments, the anti-viral formulation comprise the OC composition of the present application in an amount in the range of 0.01-99.9 wt%, 0.01-90 wt%, 0.01-60 wt%, 0.01-30 wt%, 0.01-10 wt%, 0.01-3 wt%, 0.01-1 wt%, 0.01-0.3 wt%, 0.01-0.1 wt%, 0.01-0.03 wt%, 0.03-99.9 wt%, 0.03-90 wt%, 0.03-60 wt%, 0.03-30 wt%, 0.03-10 wt%, 0.03-3 wt%, 0.03-1 wt%, 0.03-0.3 wt%, 0.03-0.1 wt%, 0.1-99.9 wt%, 0.1-90 wt%, 0.1-60 wt%, 0.1-30 wt%, 0.1-10 wt%, 0.1-3 wt%, 0.1-1 wt%, 0.1-0.3 wt%, 0.3-99.9 wt%, 0.3-90 wt%, 0.3-60 wt%, 0.3-30 wt%, 0.3-10 wt%, 0.3-3 wt%, 0.3-1 wt%, 1-99.9 wt%, 1-90 wt%, 1-60 wt%, 1-30 wt%, 1-10 wt%, 1-3 wt%, 3-99.9 wt%, 3-90 wt%, 3-60 wt%, 3-30 wt%, 3-10 wt%, 10-99.9 wt%, 10-90 wt%, 10-60 wt%, 10-30 wt%, 30-99.9 wt%, 30-90 wt%, 30-60 wt%, 60-90 wt%, 60-99.9 wt% or 90-99.9 wt% of the anti-viral formulation.
[0082] In some embodiments, the anti-viral formulation of the present application is a moisturizer comprising the OC composition of the present application and one or more components selected from the group consisting of Aloe Barbadensis Leaf Juice, Olive Oil, Glycerin, Stearyl Alcohol, Glyceryl Stearate, PEG-100 Stearate, Simmondsia Chinensis (Jojoba), Seed Oil, Sorbitan Olivate, Lauryl Laurate, Sorbitan Stearate, Glycol Distearate, Sodium Hyaluronate, Allantoin, Cetyl Palmitate, Sorbitan Palmitate, Cetearyl Olivate, Camellia Sinensis Leaf Extract, Xanthan Gum, Phenoxyethanol, Capryl Glycol, Ethylhexylglycerin, Hexylene Glycol and Citric Acid.
[0083] In some embodiments, the anti-viral formulation of the present application comprises one or more ingredients in amounts described in Table 3. In some embodiments, the anti-viral formulation of the present application comprises all the ingredients in amounts described in Table 3.
[0084] Table 3.
[0085] Generally, for pharmaceutical use, the anti-viral formulation of the present invention is formulated as a pharmaceutical composition comprising the OC composition of the present application, at least one pharmaceutically acceptable carrier, and optionally one or more secondary pharmaceutically active compounds.
[0086] When an olive component contains an acidic group as well as a basic group, the compound can form internal salts, which can be present in the OC compositions and anti-viral formulations described herein. When an olive component contains a hydrogendonating heteroatom (e.g., NH), salts are contemplated to cover isomers formed by transfer of said hydrogen atom to a basic group or atom within the molecule. Pharmaceutically acceptable salts of the olive component include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate salts. Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline,
diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases can also be formed, for example, hemisulphate and hemicalcium salts. For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002), incorporated herein by reference.
[0087] The pharmaceutically acceptable carrier includes, but is not limited to, diluents, binders, lubricants, disintegrators, fillers, pH modifying agents, preservatives, antioxidants, solubility enhancers, and coating compositions.
[0088] The pharmaceutical composition of the present invention can be prepared in a manner known per se, which usually involves mixing the OC composition according to the disclosure with one or more pharmaceutically acceptable carriers, and, if desired, in combination with other pharmaceutical active compounds when necessary under aseptic conditions. Reference is again made to U.S. Pat. Nos. 6,372,778, 6,369,086, 6,369,087 and 6,372,733 and the further references mentioned above, as well as to the standard handbooks, such as the latest edition of Remington's Pharmaceutical Sciences. The pharmaceutical composition is typically made in a unit dosage form, and can be suitably packaged, for example in a box, blister, vial, bottle, sachet, ampoule or in any other suitable single-dose or multi-dose holder or container (which can be properly labeled); optionally with one or more leaflets containing product information and/or instructions for use. Generally, such unit dosages will contain from 1 to 2000 mg (e.g., 10, 25, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 mg) per unit dosage.
[0089] The OC composition or the anti-viral formulation of the present application olive compounds can be administered by a variety of routes including the oral, ocular, rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal routes, depending mainly on the specific preparation used. The OC composition or the anti-viral formulation of the present application will generally be administered in an "effective amount", by which is meant any amount of each olive compound that, upon suitable administration, is sufficient individually, collectively or synergistically to achieve the desired therapeutic or prophylactic effect in the subject to which it is administered.
[0090] The anti-viral formulations described herein can be formulated for modified or controlled release. Examples of controlled release dosage forms include extended-release dosage forms, delayed release dosage forms, pulsatile release dosage forms, and combinations thereof. Formulations with different drug release mechanisms described above can be combined in a final dosage form comprising single or multiple units. Examples
of multiple units include, but are not limited to, multilayer tablets and capsules containing tablets, beads, or granules An immediate release portion can be added to the extended-release system by means of either applying an immediate release layer on top of the extended-release core using a coating or compression process or in a multiple unit system such as a capsule containing extended and immediate release beads.
[0091] In one embodiment, the OC composition of the present application is formulated for topical administration. Suitable topical dosage forms include lotions, creams, ointments, and gels. A "gel" is a semisolid system containing a dispersion of the active agent, i.e., olive compounds in a liquid vehicle that is rendered semisolid by the action of a thickening agent or polymeric material dissolved or suspended in the liquid vehicle. The liquid can include a lipophilic component, an aqueous component or both. Some emulsions can be gels or otherwise include a gel component. Some gels, however, are not emulsions because they do not contain a homogenized blend of immiscible components. Methods for preparing lotions, creams, ointments, and gels are well known in the art.
[0092] The OC composition of the present application can be stored as a lyophilized powder under aseptic conditions and combined with a sterile aqueous solution prior to administration. The aqueous solution used to resuspend the OC composition can contain pharmaceutically acceptable auxiliary substances as required to approximate physical conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, as discussed above. Alternatively, the OC composition can be stored as a suspension, preferable an aqueous suspension, prior to administration.
Ill, Methods Of Use
[0093] Another aspect of the present application relates to a method of preventing, treating, or ameliorating symptoms of a viral infection with the OC composition or formulation of the present application. In some embodiments, the method comprises the step of administering to a subject in need of such treatment, an effective amount of the OC composition or formulation of the present application.
[0094] In some embodiments, the subject is infected with, or is at risk of being infected by, a coronavirus. In some embodiments, the subject is infected with, or is at risk of being infected by a human SARS CoV-2 isolate, such as Wuhan-Hu-1 (NC_045512.2) and any CoV-2 isolates comprising a genomic sequence set forth in GenBank Accession Nos., such as MT079851 In some embodiments, the viral infection caused by a.l, MT470137.1, MT121215.1, MT438728.1, MT470115.1, MT358641.1, MT449678.1, MT438742.1, LC529905.1, MT438756.1, MT438751.1, MT460090.1, MT449643.1, MT385425.1,
MT019529.1, MT449638.1, MT374105.1, MT449644.1, MT385421.1, MT365031.1, MT385424.1, MT334529.1, MT466071.1, MT461669.1, MT449639.1, MT415321.1, MT385430.1, MT135041.1, MT470179.1, MT470167.1, MT470143.1, MT365029.1, MT114413.1, MT192772.1, MT135043.1, MT049951.1; human SARS CoV-1 isolates, such as SARS CoV.A022 (AY686863), SARSCoV.CUHK-Wl (AY278554), SARSCoV.GDOl (AY278489), SARSCoV.HC.SZ.61.03 (AY515512), SARSC0V.SZI6 (AY304488), SARSCoV.Urbani (AY278741), SARSCoV.civetOlO (AY572035), SARSCoV.MA.15 (DQ497008); bat SARS CoV isolates, such as BtSARS.HKU3.1 (DQ022305), BtSARS.HKU3.2 (DQ084199), BtSARS.HKU3.3 (DQ084200), BtSARS.Rml (DQ412043), BtCoV.279.2005 (DQ648857), BtSARS.Rfl (DQ412042), BtCoV.273.2005 (DQ648856), BtSARS.Rp3 (DQ071615), SARS-CoV-2 Delta variants (B.1.617.2 and AY lineages), SARS-CoV-2 omicron variants (B.1.1.529), SARS-CoV-2 Alpha variants (B.1.1.7 and Q lineages) SARS-CoV-2 Beta variants (B.1.351 and descendent lineages), SARS-CoV-2 Gamma vairants (P.l and descendent lineages), SARS-CoV-2 Epsilon variants (B.1.427 and B.1.429), SARS-CoV-2 Eta vairants (B.1.525), SARS-CoV-2 Iota variants (B.1.526), SARS- CoV-2 Kappa variants (B.1.617.1), SARS-CoV-2 variants 1.617.3, SARS-CoV-2 Mu variants (B.1.621, B.1.621.1) and SARS-CoV-2 Zeta variants (P.2), as well as any subtype, clade or sub-clade thereof, including any other subgroup 2b coronavirus now known (e.g., as can be found in the GenBank® Database) or later identified in the GenBank® Database.
[0095] In some embodiments, the subject is infected with, or is at risk of being infected by, influenza A virus including subtype H1N1, H3N2, H7N9, or H5N1, influenza B virus, influenza C virus, rotavirus A, rotavirus B, rotavirus C, rotavirus D, rotavirus E, human coronavirus, SARS coronavirus, MERS coronavirus, human adenovirus types (HAdV-1 to 55), human papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, parvovirus B19, molluscum contagiosum virus, JC virus (JCV), BK virus, Merkel cell polyomavirus, coxsackie A virus, norovirus, Rubella virus, lymphocytic choriomeningitis virus (LCMV), Dengue virus, Zika virus, chikungunya, Eastern equine encephalitis virus (EEEV), Western equine encephalitis virus (WEEV), Venezuelan equine encephalitis virus (VEEV), Ross River virus, Barmah Forest virus, yellow fever virus, measles virus, mumps virus, respiratory syncytial virus, rinderpest virus, California encephalitis virus, hantavirus, rabies virus, ebola virus, marburg virus, herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes lymphotropic virus, roseolovirus, or Kaposi's sarcoma-associated herpesvirus, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E or human immunodeficiency
virus (HIV), Human T-lymphotropic virus Type I (HTLV-1), Friend spleen focus-forming virus (SFFV), Xenotropic MuLVRelated Virus (XMRV) or Zika virus.
[0096] For prophylactic or therapeutic applications, the OC composition or formulation of the present application be administered by any route, including but not limited to any of the various parenteral, gastrointestinal, inhalation, and topical (epicutaneous) routes of administration. Parenteral administration generally involves injections or infusions and includes, for example, intravenous, intraarterial, intratumoral, intracardiac, intramuscular, intravesicular (e.g., to the bladder), intracerebral, intracerebroventricular, intraosseous infusion, intravitreal, intaarticular, intrathecal, epidural, intradermal, subcutaneous, transdermal, and intraperitoneal administration. Gastrointestinal administration includes oral, buccal, sublingual and rectal administration. The route of administration may involve local or systemic delivery of the OC composition or formulation.
[0097] In certain embodiments, the OC composition of the present application are delivered transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the pharmaceutical compositions are formulated into ointments, salves, gels, or creams as generally known in the art.
[0098] As a general proposition, a therapeutically effective amount of an olive compound composition administered will be in a weight range of about 1 ng/kg body weight/day to about 100 mg/kg body weight/day whether by one or more administrations. In some embodiments, the OC composition or formulation of the present application is administered in weight range from about 1 ng/kg body weight/day to about 1 pg/kg body weight/day, 1 ng/kg body weight/day to about 100 ng/kg body weight/day, 1 ng/kg body weight/day to about 10 ng/kg body weight/day, 10 ng/kg body weight/day to about 1 pg/kg body weight/day, 10 ng/kg body weight/day to about 100 ng/kg body weight/day, 100 ng/kg body weight/day to about 1 pg/kg body weight/day, 100 ng/kg body weight/day to about 10 pg/kg body weight/day, 1 pg/kg body weight/day to about 10 pg/kg body weight/day, 1 pg/kg body weight/day to about 100 pg/kg body weight/day, 10 pg/kg body weight/day to about 100 pg/kg body weight/day, 10 pg/kg body weight/day to about 1 mg/kg body weight/day, 100 pg/kg body weight/day to about 10 mg/kg body weight/day, 1 mg/kg body weight/day to
about 100 mg/kg body weight/day and 10 mg/kg body weight/day to about 100 mg/kg body weight/day.
[0099] In some embodiments, the OC composition or formulation of the present application is administered every 4, 6, 8, 12 or 24 hours for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 days. In some embodiments, the OC composition or formulation of the present application is administered every 1, 2, 3, 4, 5, 6 or 7 days for a period of 3, 7, 14, 21 or 28 days.
[0100] In some embodiments, the OC composition of the present application is formulated as a cream or lotion or moisturizer. The method comprises the step of applying the cream or lotion to a surface of a skin for a period of 1-60 min, 1-45 min, 1-30 min, 1-15 min, 1-10 min, 1-5 min, 5-60 min, 5-45 min, 5-30 min, 5-15 min, 5-10 min, 10-60 min, 10-45 min, 10-30 min, 10-15 min, 30-60 min, 30-45 min, 45-60 min.
[0101] Another aspect of the present application relates to a method for preventing viral transmission. The method comprises the step of treating a surface with an effective amount of an anti-viral composition comprising the OC composition of the present application for a desired period of time to inactive virus on the surface. In some embodiments, the anti-viral composition is formulated as a cream, lotion or moisturizer. In some embodiments, the anti-viral composition is formulated as a moisturizer with ingredients shown in Table 3.
[0102] Another aspect of the present application relates to a method for preventing viral infection or ameliorating a symptom of a viral infection in a subject. The method comprises the step of administering to the subject an effective amount of a dietary supplement comprising the OC composition of the present application
[0103] Another aspect of the present application relates to a method for preventing viral infection or ameliorating a symptom of a viral infection in a subject. The method comprises the step of administering to the subject an effective amount of the OC composition of the present application, wherein the OC composition is formulized in an aerosol and wherein the aerosol is administered by inhalation.
[0104] Combination Therapy
[0105] In some embodiments, the method of the present application further comprises a step of administering to the subject one or more secondary active compounds. The one or more secondary active compounds may be administered before, after or concurrently with the OC composition or formulation of the present application. Examples of the secondary active compounds include, but are not limited to, other antiviral agents,
analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, anxiolytics, sedatives, hypnotics, antipsychotics, bronchodilators, anti-asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, anorectics, and anti-narcoleptics.
[0106] Examples of other antiviral agents include, but are not limited to, abacavir, acyclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, balapiravir, BCX4430, boceprevir, cidofovir, combivir, daclatasvir, darunavir, dasabuvir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, favipiravir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, GS-5734, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type III, interferon type II, interferon type I, lamivudine, ledipasvir, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, NITD008, ombitasvir, oseltamivir, paritaprevir, peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, simeprevir, sofosbuvir, stavudine, telaprevir, telbivudine, tenofovir, tenofovir disoproxil, Tenofovir Exalidex, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine zalcitabine, zanamivir, and zidovudine.
[0107] The present application is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents, and published patent applications cited throughout this application, as well as the Figures and Tables, are incorporated herein by reference.
EXAMPLES
Example 1: Methods
[0108] Viruses and cells.
[0109] SARS-CoV-2 (JPN/TY/WK-521 strain), variant strains of SARS-CoV-2, including UK variant strain (hCoV-19/Japan/QHN001/2020), Brazilian variant strain (hCoV- 19/Japan/TY7-501/2021), South African variant strain (hCoV-19/Japan/TY8-612/2021), Delta variant strain (hCoV-19/Japan/TYl l-927-Pl/2021) were obtained from the National Institute of Infectious Diseases (Tokyo, Japan). The VeroE6/TMPRSS2 cell line, which was established in the National Institute of Infectious Diseases, was obtained from the Japanese Collection of Research Bioresources (Osaka, Japan, Cell No. JCRB1819). For passaging, VeroE6/TMPRSS2 cells were cultured in Dulbecco’s Modified Eagle’s minimal essential medium (DMEM; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% fetal bovine serum, 2 mM L-glutamine (FUJIFILM Wako Pure Chemical Co., Osaka, Japan), 0.15% NaHCOi (FUJIFILM Wako Pure Chemical Co.), 2 μg/ ammLphotericin B (Bristol- Myers Squibb Co., New York, NY, USA), 100 μg/m kaLnamycin (Meiji Seika Pharma Co., Ltd., Tokyo, Japan), and 100 μg/mL G418 disulfate aqueous solution (Nacalai Tesque Inc., Kyoto, Japan). After inoculation with SARS-CoV-2, VeroE6/TMPRSS2 cells were cultured in viral growth medium (VGM) composed of DMEM supplemented with 1% fetal bovine serum, 20 mM L-glutamine, 0.15% NaHCOi. 2 μg/m amLphotericin B, and 100 μ ogf/mL kanamycin for 3 days. Viral stocks were obtained from cell culture supernatants (VGM containing SARS-CoV-2) and stored at -80°C [viral titers: 6.90 to 7.25 logw 50% tissue culture infective doses (TCIDso)/mL]. SARS-CoV-2 was handled in the biosafety level 3 facility.
[0110] Preparation of HIDROX® 12% powder
[0111] Olives are crushed in water to form an olive slurry. The aqueous portion of the slurry (“vegetation water” or “olive juice”) is separated, collected and acidified with food grade citric acid to a specific pH range. The acid-treated olive juice is filtrated and freeze dried to produce a powder comprising about 12% phenolic compounds (HIDROX® freeze-dried powder 12%).
[0112] Preparation of HIDROX® solution
[0113] In an exemplary method for preparing HIDROX® solution, 1 g of HIDROX® 12% (Oliphenol LLC., CA, USA) powder was dissolved in 10 mL of phosphate- buffer saline (PBS) and a centrifugation (850 x g, 10 min) was performed. The aqueous layer collected was stored at -30°C and used as the stock of 100 mg/mL HIDROX® solution. For
the preparation of 3 -Hydroxy tyrosol (HT) solution, 1 g of 3-Hydroxytyrosol (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) was dissolved in 10 mL of PBS and the stock of 100 mg/mL HT solution was also stored at -30°C. Various concentrations of HIDROX® and HT solutions were prepared by diluting the stock solutions with PBS before using. In addition, OLIVENOL™ plus+ Healing Moisturizer (Oliphenol, LLC) containing 2%, 5%, or 10% HIDROX® was prepared as the HIDROX®-containing cream. The HIDROX®-free (0%) base ingredients of OLIVENOL™ plus+ Healing Moisturizer was used as the base control.
[0114| Western blotting (WB)
[0115] In the experiment analyzing the impact of the test compound on the structure of viral particle, SARS-CoV-2 solution (7.25 logw TCID50/mL) was mixed with 9 times the amount of HIDROX® solution or HT solution. In the experiment analyzing the impact of the test compound on viral proteins including spike (S) protein SI subunit, S protein receptor-binding domain (RBD), S protein S2 subunit, and nucleocapsid (N) protein, these recombinant viral proteins were mixed with HIDROX® solution or HT solution. The product information of these recombinant proteins is shown in Table 4. The final concentration of HIDROX® and HT in the mixture was 0.90 mg/mL. As a diluent control, PBS was mixed with the viral solution or recombinant proteins. The final concentration of recombinant proteins in the mixture was approximately 10 μg./ ImnL the experiment analyzing the interaction of HIDROX® or HT with carbohydrate chains expressed on S proteins, approximately 10 μg/mL of recombinant S proteins (SI subunit, RBD, and S2 subunit) were incubated at 37°C overnight with or without 6500 units/mL of PNGase F PRIME™ Glycosidase (N-Zyme Scientifics LLC., PA, USA). The glycosidase-treated or untreated proteins were mixed with PBS, HIDROX® solution, or HT solution. The final concentration of HIDROX® and HT in the mixtures was 0.90 mg/mL.
[0116] These mixtures were placed at 25 °C for 0 hr (no reaction time) or 24 hr and then mixed with sodium dodecyl sulfate (SDS)-buffer with 2-mercaptoethanol (FUJIFILM Wako Pure Chemical Co.). These samples were subjected to SDS- poly acrylamide gel electrophoresis (SDS-PAGE) and WB as previously described (Takeda Y et al., Viruses 2020, 12:699). S protein SI subunit, S protein RBD, S protein S2 subunit, and N protein were detected using primary and secondary antibodies as shown in Table 4.
[0117] Table 4. Recombinant proteins and antibodies.
*Purchased from Sino Biological Inc., Beijing, China
^Purchased from Elabscience Biotechnology Inc., TX, USA
^Purchased from Sigma-Aldrich, Inc., Saint Louis, MO, USA
[0118] Real-time RT-PCR
[0119] SARS-CoV-2 solution (7.25 logw TCID50/mL) was mixed with 9 times the amount of HIDROX® solution or HT solution. The final concentration of HIDROX® and HT in the mixture was 0.90 mg/mL. As a diluent control, PBS was mixed with the viral solution. These mixtures were placed at 25 °C for 0 hr (no reaction time) or 24 hr and then RNA was extracted using ISOGEN-LS (Nippon Gene, Tokyo, Japan) according to the manufacturer protocol. Five-hundred ng of RNA thus obtained was reverse transcribed using FastGene cDNA Synthesis 5x ReadyMix OdT (NIPPON Genetics Co, Ltd., Tokyo, Japan). Then real-time RT-PCR was performed using EagleTaq Master Mix with ROX (F. Hoffmann-La Roche Ltd., Basel, Switzerland) with the primers and probe as described in Shirato K et al., Jpn. J. Infect. Dis 2020, 73:304-307. The real-time RT-PCR conditions were: 50°C for 2 min; 95 °C for 10 min; 45 cycles of 95°C for 15 sec and 50°C for 1 min.
[0120] Test solutions
[0121] 1.0 g of HIDROX® 12% (Oliphenol LLC., CA, USA) was dissolved in 10 mL of phosphate-buffered saline (PBS) and centrifuged at 850 x g for 10 min. The aqueous
layer collected was stored at -30°C as a 100 mg/mL HIDROX® stock solution. A 1.0 mg/mL of HIDROX® solution was prepared by dilution of the stock solutions with PBS. PBS was used as a control solution.
[0122] Evaluation of direct virucidal activity of test solutions
[0123] A viral solution (VGM containing variant SARS-CoV-2) was mixed with nine volumes of 1.0 mg/mL of HIDROX® solution. The final concentrations of HIDROX® in the mixture was 0.9 mg/mL. As a diluent control, PBS was mixed with the viral solution. The mixtures were incubated at 25 °C for 3 or 24 h and then inoculated into the cells, and a tenfold serial dilution was performed. After a 3 d incubation of the cells at 37°C, a cytopathic effect was observed, and the viral titer ( log10 TCID50/mL) was calculated using the Behrens- Karber method. The detection limit of the viral titer in each test solution group was determined based on the cytotoxicity of each test solution. The detection limits of the viral titers in the groups treated with PBS or HIDROX® solution were set to 1.25 and 2.25 logic TCID50/mL, respectively.
[0124] Statistical analysis
[0125] Student’s t test was performed to determine statistically significant differences between a control group (e.g, PBS) and each test sample group (e.g., HIDROX®- treated). P values of less than 0.05 were considered statistically significant.
[0126] Example 2: Time- and concentration-dependent virucidal activity of HIDROX® solution against SARS-CoV-2.
[0127] A HIDROX® solution was prepared in accordance with the schematic illustration depicted in FIG. 1 and the specific method steps outlined in Example 1. The virucidal activity of the HIDROX® solution against SARS-CoV-2 (JPN/TY/WK-521 strain) was evaluated in accordance with the experimental protocol depicted in FIG. 2 and the corresponding method steps below. Briefly, a SARS-CoV-2 solution (7.25 logw TCID50/mL) was mixed with 9 times the amount of HIDROX® solution or HT solution. The final concentrations of HIDROX® and HT in the mixture were 0.45-11.25 mg/mL and 0.05-0.90 mg/mL, respectively. As a diluent control, PBS was mixed with the viral solution. These mixtures were placed at 25°C for 5 min-24 hr and then inoculated into cells, and a tenfold serial dilution was performed. After incubation for 3 days, a cytopathic effect caused by inoculated SARS-CoV-2 was observed and the viral titer (logw TCID50/mL) was calculated using the Behrens-Karber method (Karber, G., Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakoi. 1931,162, 480-483; doi:10.1007/BF01863914).
[0128] The detection limits for viral titers in each test group were determined based on the cytotoxic concentration of each test solution. The detection limit was set higher in the group treated with a solution of higher cytotoxicity. PBS, 0.45 mg/mL HIDROX®, and 0.05 mg/mL HT solutions did not show any cytotoxicity, and the detection limit of the viral titer in the groups treated by these solutions was set to 1.25 logio TCID50/mL, according to the viral titer calculation. In contrast, >0.90 mg/mL HIDROX® and 0.90 mg/mL HT solutions demonstrated cytotoxicity. The detection limits in the groups treated with 0.90, 4.50, 5.63 mg/mL HIDROX®, and 0.90 mg/mL HT solutions were set to 2.25 logio TCID5o/mL and the detection limit in the group treated by 11.25 mg/mL HIDROX® solution was set to 3.25 logio TCID50/mL, respectively.
[0129] FIG. 3, panels A and B show the time- and concentration-dependent virucidal activities of HIDROX® against SARS-CoV-2. In these experiments, SARS-CoV-2 was mixed with HIDROX® such that the final concentrations of HIDROX® in each mixture were 0.45, 0.90, and 4.50 mg/mL (FIG. 1, panel A) or 5.63 and 11.25 mg/mL (FIG, 1, panel B). As a diluent control, PBS was mixed with the viral suspension. The mixtures were incubated at 25 °C for 0.5-24 h (Panel A) or 5 min (Panel B) and then the viral titers were evaluated.
[0130] As shown in FIG. 3, panel A, the HIDROX® solutions clearly showed time- and concentration-dependent SARS-CoV-2-inactivating activity. The 4.50 mg/mL of HIDROX® solution inactivated 99.68% of virus (2.50 logio TCID50/mL reduction of viral titer) in 0.5 hr reaction time. The 0.90 mg/mL and 0.45 mg/mL of HIDROX® solutions inactivated 98.53% and 90.00% of virus (1.83 logio TCID50/mL and 1.00 logio TCID50/mL reduction) in 1.0 hr reaction time, respectively (FIG. 3, panel A). In addition, the 5.63 mg/mL and 11.25 mg/mL of HIDROX® solutions inactivated 86.67% and 95.78% of virus (0.88 logio TCID50/mL and 1.38 logio TCID50/mL reduction) in 5 min reaction time, respectively (FIG. 1, panel B). In FIG. 3, the results are presented as the mean ± SD, where n = 3-4 per group. Student’s t-test was performed to evaluate the statistically significant difference between the PBS and HIDROX® groups; * p < 0.05; ** p < 0.01; *** p < 0.001.
[0131] Example 3. Time-dependent virucidal activity of HIDROX® solution against variant SARS-CoV-2 strains.
[0132] To extend the HIDROX® virucidal analysis to other SARS-CoV-2 variant strains, time-dependent virucidal activity of HIDROX® solution against four variant SARS- CoV-2 strains were determined according to the experimental protocol depicted in FIG. 4.
[0133] As shown in FIG. 5, HIDROX® was found to inactivate all four different SARS-CoV-2 variants. At a concentration of 0.9 mg/mL, HIDROX® inactivated >99% all the variant strains of SARS-CoV-2 in 3 h and inactivated >99.9% of the variant strains of SARS-CoV-2 in 24 h. The viral titers in the HIDROX® groups were below the detection limit.
[0134] Example 4. Comparison of virucidal activity of HIDROX® solution and HT solution against SARS-CoV-2.
[0135] Next, the virucidal activities of HIDROX® solution and HT solution against SARS-CoV-2 were compared. In this experiment, FIG. 6, panel A depicts the experimental protocol for evaluating the comparative virucidal activities of HIDROX® and HT against SARS-CoV-2. Briefly, SARS-CoV-2 solutions (7.25 logw TCID50/mL) were mixed with 9 times the amount of HIDROX® solution or HT solution and incubated at 25 °C for 3 or 24 hr. The final concentration of HIDROX® in the mixture was 0.90 mg/mL; the final concentration of HT in the mixtures were 0.90 mg/mL and 0.05 mg/mL. PBS was mixed with the viral suspension as the diluent control. Following the incubations at 25 °C for 3 or 24 hr, the mixtures were inoculated to cells and incubated for 3 days. At this point, a cytopathic caused by inoculated SARS-CoV-2 was observed and the viral titers (logic TCID50/mL) in each group were calculated using the Behrens-Karber method. The detection limit for the viral titer in each test group was determined based on the cytotoxic concentration of each test solution.
[0136] FIG. 6, panel B shows the results of the experiment depicted in panel A. In panel B, the detection limits of viral titer are 1.25 log1050% tissue culture infective dose (TCIDso)/mL in the PBS and HT (0.05 mg/mL) groups and 2.25 logw TCID50/mL in the HIDROX® (0.9 mg/mL) and HT (0.90 mg/mL) groups. Results are indicated as mean ± SD (n = 4 per group). Student’s t-test was performed to evaluate the statistically significant difference between the PBS group and each test group; * p < 0.05; *** p < 0.001.
[0137] In addition to the same concentration (0.90 mg/mL) of HIDROX® and HT in the solutions, a 0.05 mg/ml of HT solution corresponding to the concentration of HT contained in the 0.90 mg/mL HIDROX® solution was tested. Following a 3 hr reaction time, the 0.90 mg/mL HIDROX® solution caused significant virucidal activity, while the 0.90 mg/mL and 0.05 mg/mL HT solutions did not. While both of 0.90 mg/mL of HIDROX® and HT solutions inactivated >99.98% of virus (>3.63 logw TCID50/mL reduction; the viral titer was below the detection limit) in 24 hr reaction time, the virucidal activity of 0.05 mg/mL of HT solution was limited (0.63 logw TCID50/mL reduction) (FIG. 6, panel B). These results
indicate that the SARS-CoV-2-inactivating activity of HIDROX® is more potent than that of pure HT.
[0138] Example 5. Virucidal activity of HIDROX® in SARS-CoV-2 infected cells at various concentrations.
[0139] Virucidal activity of HIDROX® in SARS-CoV-2 infected cells at various concentrations was evaluated. FIG. 7, panel A shows an experimental protocol for examining the direct virucidal activity of HIDROX® against SARS-CoV-2 at various concentrations (6.25 - 100 mg/ml). FIG. 7, panel B shows the virucidal activity of HIDROX® at various concentrations in accordance with the schematic diagram in FIG. 7.
[0140] Example 6. Inhibitory effect of HIDROX® on SARS-CoV-2 proliferation.
[0141] Inhibitory effect of HIDROX® on SARS-CoV-2 proliferation was evaluated. FIG. 8 shows an experimental protocol for evaluating the inhibitory effect of HIDROX® (pH 7.4) on virus proliferation in host cells. FIG. 9 shows the results of the experiment described in FIG. 8.
[0142] Example 7. Virucidal activity of HIDROX® in SARS-CoV-2 infected cells at low concentrations
[0143] Virucidal activity of HIDROX® at low concentrations was evaluated in SARS-CoV-2 infected cells. FIG. 10 shows an experimental protocol for examining the direct virucidal activity of HIDROX® against SARS-CoV-2 at low concentrations (0.5 - 5.0 mg/ml). FIG. 11 shows the results of the experiment described in FIG. 10.
[0144] Example 8. Cytotoxicity of HT compared to HIDROX®.
[0145] The cytotoxicity of HT and HIDROX® was evaluated. FIG. 12 shows the cytotoxicity of HT (0 - 50 pg/ml) compared to HIDROX® (0 - 250 pg/ml).
[0146] Example 9. Comparison of the virucidal activities of HIDROX® and HT against SARS-CoV-2.
[0147] FIG. 13, panel A shows an experimental protocol for comparing the virucidal activities of HIDROX® and HT against SARS-CoV-2 at 1.0 mg/ml and 0.05 mg/ml. FIG. 13, panel B shows the result of the experiment described in panel A.
[0148] Example 10. Time- and concentration-dependent virucidal activity of HIDROX®-containing cream against SARS-CoV-2.
[0149] The virucidal activity of HIDROX®-containing cream, which is assumed to be used for topical application like a hand cream, against SARS-CoV-2 was evaluated. Briefly, 20mg of test cream was applied on 2.25 cm2 (1.5 cm x 1.5 cm) of polyethylene
terephthalate film (AS ONE Co., Ltd., Osaka, Japan). The lid of 12 well plate (Nunc, Rochester, NY, USA) was turned over and 5.25 logio TCID50/60 ml of SARS-CoV-2 solution was dropped to the inside of well-lid. The viral solution was covered by the cream-coated film. In this setting, the cream was in contact with the viral solution. The 12 well plate was placed for 10 min-6 hr at 25°C. After the predetermined reaction times, the viral solution was recovered. This viral solution was inoculated into cells and tenfold serial dilutions were prepared. After incubation for 1 hr at 37 °C, the cell culture medium containing virus was removed and new VGM was added. After incubation for 3 days at 37°C, the viral titer (logic TCID50/mL) was calculated.
[0150] Upon application of 20 mg of HIDROX®-containing cream to 2.25 cm2 of film clearly showed time- and concentration-dependent SARS-CoV-2-inactivating activity (FIG. 14). The 10% and 5% HIDROX®-containing creams inactivated 94.38% and 79.47% of virus (1.25 logic TCID50/mL and 0.69 logic TCID50/mL reduction of viral titer) in 10 min reaction time, respectively. The 2% HIDROX®-containing cream also inactivated 94.38% of virus (1.25 logio TCID50/mL reduction of viral titer) in 30 min reaction time (FIG. 14).
[0151] Example 11. Impact of HIDROX® and HT on SARS-CoV-2 structural proteins.
[0152] To evaluate the impact of HIDROX® and HT on SARS-CoV-2 structural proteins, the S protein SI subunit, S protein S2 subunit, and N protein expressing on virus particles treated by PBS (diluent control), HIDROX®, and HT were analyzed by WB. The results of WB to detect S protein SI subunit and S2 subunit on PBS treated-viruses showed two specific bands with different molecular weights; one was around 240 kDa and the other was around 120 kDa. It is presumed that the higher molecular weight band was the full-length S protein and the lower molecular weight band was the cleaved S protein, corresponding S 1 or S2 subunits. While HIDROX®- and HT-treated viruses also showed these two bands in 0 hr (no reaction time), the intensity of these bands became weaker and the other bands or ladder with >250 kDa was appeared in 24 hr reaction time (FIG. 15, panel A, left and middle).
[0153] In the WB to detect N protein, there was no difference in the intensity of specific band among PBS-, HIDROX®-, and HT-treated viruses in both of 0 hr and 24 hr reaction times (FIG. 15, panel A, right). Next, to evaluate the impact of HIDROX® and HT on RBD located on S protein SI subunit, the WB to detect RBD was performed. While the main band with ~65 kDa was observed among all of PBS-, HIDROX®, and HT-treated recombinant proteins in 0 hr, this band was almost disappeared and the strong band with
>150 kDa was appeared by HIDROX®-treatment in 24 hr reaction time. On the other hand, both of the two bands with ~65 kDa and >150 kDa were detected in HT-treated protein in 24 hr reaction time (FIG. 15, panel B, left).
[0154] To evaluate the direct impact of HIDROX® and HT on N protein, the recombinant N protein was mixed with PBS, HIDROX®, or HT solution. The intensity of specific band with ~50 kDa was slightly weaker in HIDROX®-treated protein than that in PBS-treated protein in 24 hr reaction time, but such a decrease of the intensity was not observed in HT-treated protein. In addition, several bands with >100 kDa were appeared by both of HIDROX®- and HT-treatment (FIG. 15, panel B, right). These results indicate that HIDROX® and HT induce some changes that affect the molecular weight for viral structural proteins, especially S proteins. In addition, these results also suggest that such a mode of action of HIDROX® is stronger than that of HT.
[0155] Example 12. Interaction of HIDROX® or HT with carbohydrate chains expressed on S proteins.
[0156] Since S protein of SARS-CoV-2 is highly glycosylated by post- translational modification. The interaction of HIDROX® and HT with carbohydrate chains attached to S protein was evaluated. The recombinant S protein SI subunit, RBD, and S2 subunit which were non-treated (glycosylated) or treated by glycosidase (deglycosylated) beforehand were mixed with PBS, HIDROX®, or HT solution. After 24 hr reaction time WB was performed. In the WB to detect SI subunit, the specific bands with ~150 kDa and ~75 kDa were detected in glycosylated- and deglycosylated-proteins treated by PBS, respectively. However, this deglycosylated-band with ~75 kDa were disappeared by HIDROX®-treatment. In addition, the other bands with >250 kDa were appeared by HIDROX®- and HT-treatments in both of glycosylated- and deglycosylated-proteins (FIG. 16, left). In the WB to detect RBD, the molecular weight of the specific band observed in PBS-treated protein was slightly reduced by deglycosylation. Both of these glycosylated- and deglycosylated-bands were almost disappeared by HIDROX®-treatment, and the other bands with >150 kDa were appeared by both of HIDROX®- and HT-treatments (FIG. 16, middle). In the WB to detect S2 subunit, the molecular weight of the main specific band observed in PBS-treated protein was slightly reduced by deglycosylation. In addition, some weak bands with >'250 kDa were also observed in PBS-treated proteins. However, both of glycosylated- and deglycosylated- main bands were disappeared by HIDROX®-treatment. On the other hand, the bands or ladder with >'250 kDa remained (or appeared) in HIDROX®- and HT-treated proteins (FIG.
16, right). These results indicate that the site of action of HIDROX® and HT on S proteins was not carbohydrate chains.
[0157] Example 13. Impact of HIDROX® and HT on SARS-CoV-2 genome.
[0158] To evaluate the impact of HIDROX® and HT on SARS-CoV-2 genome, the viral RNA was extracted from PBS-, HIDROX®-, and HT-treated viruses and real-time RT-PCR was performed. While the Ct values were similar among all treatment groups in 0 hr (no reaction time), these values were 3.19 and 2.63 higher in HIDROX® and HT groups than that of PBS group in 24 hr reaction time, respectively. This increase of Ct values meant that the amount of viral RNA was 9.13 and 6.17 times lower in HIDROX® and HT groups than that of PBS group, respectively (FIG. 17). This result indicates that HIDROX® and HT disrupt viral genome.
[0159] Example 14. Cytotoxicity of HT compared to HIDROX® in MDCK cells.
[0160] FIG. 18 shows the cytotoxicity of HT (0 - 500 μg/ml) compared to HIDROX® (0 - 500 μg/ml) in MDCK cells, the host cells for influenza (H1N1) in the experiment described in FIG. 19.
[0161] Example 15. Virucidal activity of HIDROX® against influenza- infected MDCK cells.
[0162] Virucidal activity of HIDROX® was evaluated in influenza virus-infected MDCK cells. FIG. 19, panel A shows an experimental protocol for evaluating the virucidal activity of HIDROX® against influenza-infected MDCK cells at various different concentrations and incubation periods. FIG. 19, panel B shows the result of the experiment described in panel A.
[0163] Example 16. Analysis of the OLIVENOL™ dietary supplement.
[0164] OLIVENOL™ is a dietary supplement. The amount of phenolic compounds in the OLIVENOL™ and two different batches of vegetation water from olive oil processing (CR43 and CR21) are shown in Table 5. Gas chromatographic profiles in the time range 15-25 min, generally attributable to simple phenols, have shown that OLIVENOL™ composition is qualitatively similar to that of the phenolic fraction of extravirgin olive oil (FIG. 20), notwithstanding the quantitative contents being different. In particular, the concentrations of tyrosol and hydroxytyrosol in OLIVENOL™ are about 50 and 30-fold higher than that present in the extra- virgin olive oil studied.
[0165] Table 5. Phenolic compounds in the OLIVENOL™ dietary supplement and in the aqueous phase of vegetation waters (OVW) from olive oil processing batch CR43
and CR21. The analyzed lot of OLIVENOL™ was obtained from the aqueous phase of vegetation waters from olive oil processing batch CR43. Data is expressed as the mean (n=4) ± standard deviation.
[0166] To obtain a product suitable for the market, the transformed OVWs can be subjected to centrifugation, filtration and pasteurization processes. In order to evaluate the effects of these treatments, the phenolic composition of the OLIVENOL™ was compared to that of the VW CR43 used for its production. After the treatments, no significant qualitative (FIG. 20) or quantitative (Table 5) differences were observed in the aqueous phase compositions from both samples. In particular, the increase of the OLIVENOL™ dry weight can be attributed to the presence of vegetable glycerin and vegetable gum used as emulsifiers and sweeteners in the final product. As matter of fact, the total phenolic content was almost the same (Table 5). Moreover, the use of centrifugation and filtration resulted in increased amounts of hydroxytyrosol and citric acid in the studied food supplement. These water soluble molecules can be entrapped by adsorption in the solid olive-mill phase, mainly containing polymeric compounds such as lignin, hemicellulose and cellulose. Extracts from this solid phase, in fact, also after an extensive centrifugation, showed low amounts of hydroxytyrosol and citric acid, about 0.54 and 7.49 pg per mg of dry weight, respectively.
[0167] The results also show that the industrial process is highly reproducible and the produced OVWs are stable at room temperature. As matter of fact, the OVW CR21,
produced about three years before OVW CR43, revealed a phenolic composition similar to that of the OVW CR43 (Table 5).
[0168] Example 17. Conversion of vegetation waters into hydroxytyrosol-rich mixtures by acidic hydrolysis.
[0169] In the OVW collected after centrifugation of the liquid-phase mixture that includes olive oil and vegetation water, a high content of oleuropein and other simple phenols with a higher solubility in aqueous phase were found (Table 6). After 6 months, in the OVWs treated and not treated with citric acid, the oleuropein was semi-quantitatively converted in hydroxytyrosol (Table 6): using an authentical standard, in fact, the occurrence of a hydrolytic process of the oleuropein at the acidic pH of OVW has been demonstrated. Moreover, only a slightly higher concentration of tyrosol was observed after the incubation in both treated and untreated OVWs. The studied OVW was obtained from depitted olives so explaining the lower initial tyrosol amount, being this simple phenol present in the seed and in the stone at levels comparable to those revealed in the pulp. In addition, the absence of the tyrosol derivative nuzhenide, which is exclusively present in the seeds, supports the small increase of the tyrosol amount after the proposed incubation.
[0170] Table 6. Phenolic compounds in the aqueous phase of vegetation water treated and not treated with citric acid (1.5%) at time 0 and after 6 months. The data are expressed as mean (n=4) ± standard deviation.
[0171] After 6 months of incubation in the absence and in the presence of citric acid, a significant decrease in the concentrations of both 3,4-dihydroxybenzoic and syringic acids was observbed, whereas the amount of vanillic acid increased, especially in the treated OVW. On the other hand, the content of 3-hydroxy, 4-metoxy-phenylacetic acid increased in the untreated OVW but decreased in the presence of citric acid (Table 6). In the analyzed mixtures, the hydroxytyrosol production has prevalently involved the acid-catalyzed hydrolysis of oleuropein. However, the grown of yeast and fungi in the OVW after the incubation in acidic environment (data not shown), indicate that metabolic processes occur, even if they seem not involved in the hydroxytyrosotformation,-
[0172] It is known that several aerobic bacterial strains capable of degrading several of the monocyclic aromatic compounds, had been isolated in the OVWs. In particular, specific enzyme analyses have showed the occurrence of o-demethylating activities that can explain the lower content of syringic acid after the proposed incubation. Furthermore, a demonstrated ring-cleavage activity towards 3,4-dihydroxybenzoic acid in strains from OVWs supports the decreased amount of this simple phenol in these experiments. Moreover, the chemical and/or enzymatic degradation of lignin can support the higher content of vanillic acid after the incubation at acidic pH.
[0173] On the other hand, the total phenol amount in the sample incubated in the presence of citric acid (Table 6) indicates that the OVWs are stable in acidic environment. The presence of citric acid, as demonstrated for the ascorbic acid, can contribute to keep the phenols concentration constant avoiding the quinones accumulation and the formation of insoluble polymers, due to the direct oxidation by molecular oxygen. In the OVWs, these polymeric phenolic compounds give the sludge characterized by a recalcitrant brownish black color. After the addition of citric acid, an immediate significant decolorization of the OVW persisting during the incubation time, and no increase of solid residue was revealed, indicating an effective degradation of the polymeric fraction.With regard to quinone accumulation in the presence of citric acid, a higher amount of hydroxytyrosol, 3,4- dihydroxybenzoic acid and gallic acid, compounds with chemical structures more susceptible to the oxidation due to the presence of two or more hydroxyl groups were observed (Table 6).
[0174] The calculated concentrations of phenolic compounds after 6 months of incubation in acidic environment (Table 6) were similar to those calculated in the OVWs CR43 and CR21 (Table 5), indicating that after this time the OVW transformation is almost over, and supporting the hypothesized stabilizing effect of the citric acid. Even if the phenols composition determined for the treated and untreated OVWs after 6 months of incubation
(Table 6) seems quite similar, the advantage in using citric acid to transform the OVW is pointed out by the qualitative GC profiles of both samples (FIG. 21). In the presence of the organic acid, a number of peaks (FIG. 21, panel C) lower than observed in untreated OVW were identified (FIG. 21, panel B): These results, reflected in a higher total phenol content in about the same dry weight (Table 6), suggest that when using citric acid, a mixture can be produced that is enriched in phenols with reduced concentrations of non-phenolic compounds. In order to verify this, GC-MS analyses were carried out to characterize the composition of the treated and the untreated OVWs after the incubation. By spectrum matching and library searching in the NIST/EPS/NIH Mass Spectral Library Database, two small peaks with the m/z 280 fragment related to aglyconic P-phenyl ethanol derivatives of hydroxytyrosol were identified only in the treated OVW, and four significant peaks containing the m/z 280 and 193 fragments, consistent with oleuropein aglyconic forms.
[0175] Furthermore, by spectrum matching and library searching, several non- phenolic compounds were identified, especially carbohydrates and secondary metabolites, which is consistent with the occurrence of metabolic processes in treated and untreated OVWs (Table 7).
[0176] Table 7. Compounds identified in the aqueous phase of vegetation water treated and not treated with citric acid (1.5%). The hints of the identification for each compound have a probability higher than 70%.
[0177] In the OVW at time 0, the sugars determined in high concentrations were fructose and glucose aqueous derivatives, whereas the dihydroxyacetone (in both phosphorylated and unphosphorylated forms) was the main secondary metabolite. It is believed that these compounds are metabolized in the untreated OVW in the 5 -carbon pentose sugars. These molecules are natural intermediate products, which regularly occur in the glucose metabolism of microorganisms. In particular, compounds such as xylulose, arabinose, ribose and their derivatives such as xylitol and deoxyribose, have been already identified in OVWs and are present in high amount after 6 months of incubation in untreated OVWs (Table 7). As matter of fact, in the GC-MS spectrum of the untreated OVW peaks attributable to mannose and its derivatives were identified but the probability of the identification was less than 70%. On the other hand, the high concentration of fructose, glucose, and dihydroxyacetone at time 0 can also activate the production of the identified galactose derivatives and glycerol (Table 7) from the glucose metabolism.
[0178] A significant difference in the composition of the pentose sugars was observed after the incubation in the presence of citric acid (Table 7), indicating a possible
alternative pathway for the glucose degradation. Moreover, higher concentrations of glycerol and trihydroxy-butyric acid revealed after 6 months (Table 7), according with an initial high amount of dihydroxyacetone, suggest the occurrence of a significant lipolysis. These data may indicate the occurrence of different metabolic pathways in the treated and untreated OVWs. At the moment, the presence of a different microorganism flora in the OVWs exposed to the two studied conditions of incubation cannot be excluded.
[0179] Example 18. Inhibitory effects of Olivenol plus® Essence Liquid and HIDROX® on suppression of SARS-CoV-2 proliferation.
[0180] Inhibitory effects of Olivenol plus® Essence Liquid and HIDROX® on suppression of SARS-CoV-2 proliferation was evaluated. FIG. 22, panel A, shows an experimental protocol for evaluating inhibitory effects of Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells. FIG. 22, panel B shows the results of the experiment in FIG. 22, panel A.
[0181] FIG. 23, panel A shows an experimental protocol for evaluating inhibitory effects of HIDROX® on suppression of SARS-CoV-2 proliferation in cells. FIG. 23, panel B shows the results of the experiment in FIG. 23, panel A.
[0182] Example 19. Antiviral activity of cells pre-treated with Olivenol plus® Essence Liquid and HIDROX®.
[0183] Antiviral activity of cells pre-treated with Olivenol plus® Essence Liquid and HIDROX® was evaluate. FIG. 24, panel A shows an experimental protocol for evaluating antiviral activity of cells pre-treated with Olivenol plus® Essence Liquid. Suppression of SARS-CoV-2 proliferation in cells was determined. FIG. 24, panel B shows the results of the experiment in FIG. 24, panel A.
[0184] FIG. 25 shows an experimental protocol for evaluating antiviral activity of cells pre-treated with HIDROX®. Suppression of SARS-CoV-2 proliferation in the cells was determined. FIG. 25, panel B shows the results of the experiment in FIG. 26, panel A.
[0185] Example 20. Virucidal activity of Olivenol plus® Essence Liquid and HIDROX® on suppression of SARS-CoV-2 proliferation.
[0186] FIG. 26, panel A shows an experimental protocol for evaluating direct virucidal activity of Olivenol plus® Essence Liquid on suppression of SARS-CoV-2 proliferation in cells. FIG. 26, panel B shows the results of the experiment in FIG. 26, panel A.
[0187] FIG. 27, panel A shows an experimental protocol for evaluating direct virucidal activity of HIDROX® on suppression of SARS-CoV-2 proliferation in cells. FIG. 27, panel B shows the results of the experiment in FIG. 27, panel A.
[0188] Example 21. Effects of acidic pH on HIDROX®’s virucidal activity in suppressing SARS-CoV-2 proliferation.
[0189] FIG. 28 shows an experimental protocol for evaluating the effects of acidic pH on HIDROX®’ s virucidal activity in suppressing SARS-CoV-2 proliferation in cells. FIG. 28, panel B shows the results of the experiment in FIG. 28, panel A.
[0190] Example 22. Effects of HIDROX® in suppressing proliferation of the Delta variant of SARS-CoV-2.
[0191] Delta variant of SARS-CoV-2 [hCoV-19/Japan/TYl l-927-P 1/2021] was provided by National Institute of Infectious Diseases (Tokyo, Japan). VeroE6/TMPRSS2 cell, which was established in the National Institute of Infectious Diseases, was obtained from the Japanese Collection of Research Bioresources (Osaka, Japan, Cell No. JCRB1819). For passaging, VeroE6/TMPRSS2 cells were cultured in the growth medium: Dulbecco’s Modified Eagle’s medium (DMEM; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% fetal bovine serum, 2 mM L-glutamine (Wako Pure Chemical Industries, Ltd., Osaka, Japan), 0.15% NaHCO3 (Wako Pure Chemical Industries, Ltd.), 2 pg/ml amphotericin B (Bristol-Myers Squibb Co., NY, USA), and 100 μg/mL kanamycin (Meiji Seika Pharma Co., Ltd., Tokyo, Japan). After inoculation with SARS-CoV-2, VeroE6/TMPRSS2 cells were cultured in viral growth medium (VGM) composed of DMEM supplemented with 1% fetal bovine serum, 2 mM L-glutamine, 0.15% NaHCO3, 2μg/mL amphotericin B, and 100 μg/mL kanamycin. SARS-CoV-2 was handled in the biosafety level 3 facility. The viral titer of the stock solution (VGM) ccontaini containing SARS-CoV-2) was ~6.9 loglO 50% tissue culture infective dose (TCID50)/mL.
[0192] Test solutions
[0193] The 1.0 g of HIDROX® 12% (Oliphenol LLC., CA, USA) was dissolved in 10
[0194] mL of phosphate-buffered saline (PBS), and a centrifugation (850 x g, 10 min) was performed. The aqueous layer collected was stored at -30°C as the stock of 100 mg/mL HIDROX solution. The 1.0 mg/mL of HIDROX solution was prepared by dilution of the stock solutions with PBS. PBS was used as a control solution.
[0195] Evaluation of direct virucidal activity of test solutions
[0196] Viral solution (VGM containing Delta variant of SARS-CoV-2) was mixed with nine volumes of 1.0 mg/mL of HIDROX solution. The final concentrations of HIDROX in the mixture was 0.9 mg/mL. As a diluent control, PBS was mixed with the viral solution. The mixtures were incubated at 25 °C for 3 or 24 h and then inoculated into the cells, and a tenfold serial dilution was performed. After 3 d incubation of the cells at 37°C, a cytopathic effect was observed, and the viral titer (loglO TCID50/mL) was calculated using the Behrens-Karber method. The detection limit of the viral titer in each test solution group was determined based on the cytotoxicity of each test solution. The detection limit of the viral titer in the group treated by PBS and HIDROX solution was set to 1.25 and 2.25 loglO TCID50/mL, respectively.
[0197] Statistical analysis
[0198] Student’s t test was performed to determine statistically significant differences between PBS and HIDROX groups. Statistical significance was set at p < 0.05.
[0199] FIG. 29, panel A shows the experimental protocol for evaluating the effects of HIDROX on the proliferation of the Delta variant of SARS-CoV-2 in cells. FIG. 29, panel B shows the results of the experiment in FIG. 29, panel A.
Claims
1. A method for preventing, treating or ameliorating a symptom of a viral infection in a subject, comprising the step of: administering to the subject an effective amount of an olive component composition, wherein the olive component composition comprises one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA- EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxy oleuropein, and 10- hydroxyligstroside; vanillic acid, 3-hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy- benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA- EDA, lignanes, flavonoids, elenolic acid, alpha-tocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, and lycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof.
2. The method of claim 1, wherein the olive component composition comprises hydroxytyrosol and one or more other polyphenyl compounds.
3. The method of claim 1 or 2, wherein the olive component composition further comprises one or more non-phenolic compounds selected from the group consisting of D- fructose, glucofuranoside, glucopyranoside, dihydroxyacetone, malic acid, trihydroxybutyric acid, glucitol, glycerol, propanoic acid, xylonic acid, xylulose, xylitol, arabinose, ribose, deoxyribose, galactopyranoside, ketogluconic acid and galactofuranose.
4. The method of any one of claims 1-3, wherein the olive component composition is formulated for oral administration.
5. The method of any one of claims 1-3, wherein the olive component composition is formulated for topical administration.
6. The method of any one of claims 1-3, wherein the olive component composition is formulated for inhalation.
7. The method of any one of claims 1-6, wherein the olive component composition comprises acid-treated olive juice.
8. The method of any one of claims 1-7, wherein the subject is infected with or at the risk of being infected with SARS-CoV-2 virus.
9. The method of any one of claims 1-7, wherein the subject is infected with or at the risk of being infected with influenza virus.
10. A method for preventing or reducing surface transmission of a virus, comprising the step of: applying an effective amount of an olive component composition to a surface for a period of time to inactivate a virus on the surface, wherein the olive component composition comprises one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, such as oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA- EA), oleocanthol (HPEA-EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10- hydroxyoleuropein, and 10-hydroxy ligstroside; vanillic acid, 3-hydroxy, 4- metoxyphenylacetic acid, 3,4-dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alphatocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, and lycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof.
11. The method of claim 10, wherein the olive component composition comprises acid-treated olive juice.
12. The method of claim 10 or 11, wherein the virus is SARS-CoV-2 virus or influenza virus.
13. An antiviral composition, comprising: an olive component composition, wherein the olive component composition comprises:
(1) one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA- EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxy oleuropein, and 10-hydroxyligstroside; vanillic acid, 3-hydroxy, 4-metoxyphenylacetic acid, 3,4- dihydroxy-benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA-EDA, lignanes, flavonoids, elenolic acid, alpha-tocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, and lycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof; and
(2) propanoic acid.
14. The antiviral composition of claim 13, wherein the olive component composition does not comprise syringic acid, or comprises syringic acid in an amount of less than 0.01 mg/ml.
15. An antiviral composition, comprising an olive component composition, wherein the olive component composition comprises: one or more polyphenyl compounds selected from the group consisting of hydroxytyrosol, tyrosol, tyrosol esters of elenolic acid, oleuropein, demethyloleuropein, oleuropein aglycone (3,4 DHPEA-EA), oleocanthol (HPEA- EDA), ligstroside, lingstroside aglycone (3,4 DHPEA-EA), 10-hydroxy oleuropein, and 10- hydroxyligstroside; vanillic acid, 3-hydroxy, 4-metoxyphenylacetic acid, 3,4-dihydroxy- benzoic acid, citric acid, syringic acid, gallic acid, caffeic acid, gentisic acid, 3,4 DHPEA- EDA, lignanes, flavonoids, elenolic acid, alpha-tocopherol, verbascoside, pinoresinol lignan, rutin flavonoid, secoiridoids, pinoresinol, and lycosylated, deglycosylated, phosphorylated and dephosphorylated forms thereof, wherein the antiviral composition is formulated in an aerosol for inhalation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063122893P | 2020-12-08 | 2020-12-08 | |
US17/326,146 US11951143B2 (en) | 2017-01-04 | 2021-05-20 | Olive oil use |
PCT/US2021/062213 WO2022125552A1 (en) | 2020-12-08 | 2021-12-07 | Antiviral olive extract compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4258874A1 true EP4258874A1 (en) | 2023-10-18 |
Family
ID=81973957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21904253.8A Pending EP4258874A1 (en) | 2020-12-08 | 2021-12-07 | Antiviral olive extract compositions and methods |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4258874A1 (en) |
CA (1) | CA3201770A1 (en) |
WO (1) | WO2022125552A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4139196A (en) * | 1994-11-07 | 1996-05-31 | William R. Fredrickson | Method and composition for antiviral therapy |
AU8858001A (en) * | 2000-09-01 | 2002-03-13 | Creagri Inc | Method of obtaining a hydroxytyrosol-rich composition from vegetation water |
US6455070B1 (en) * | 2001-02-15 | 2002-09-24 | East Park Research, Inc. | Composition for treating symptoms of influenza |
US20090061031A1 (en) * | 2006-07-07 | 2009-03-05 | Sylvia Lee-Huang | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus |
WO2008143137A1 (en) * | 2007-05-24 | 2008-11-27 | National University Corporation, Obihiro University Of Agriculture And Veterinary Medicine | Antiviral agent |
EP2635120A1 (en) * | 2010-08-06 | 2013-09-11 | Phyto Innovative Products Ltd | Compositions comprising oleuropeins and flavanoids and their use |
US8846114B1 (en) * | 2013-09-05 | 2014-09-30 | Oleavicin, LLC | Composition for the treatment of herpes and cold sores |
-
2021
- 2021-12-07 CA CA3201770A patent/CA3201770A1/en active Pending
- 2021-12-07 WO PCT/US2021/062213 patent/WO2022125552A1/en unknown
- 2021-12-07 EP EP21904253.8A patent/EP4258874A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022125552A1 (en) | 2022-06-16 |
CA3201770A1 (en) | 2022-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bailly et al. | Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? | |
Kim et al. | Anti-HIV activity of extracts and compounds from marine algae | |
KR102204299B1 (en) | Therapeutic agent for coronavirus comprising Elaeocarpus sylvestris extract as effective component | |
KR101782532B1 (en) | A composition comprising extract of Angelica dahurica or furanocoumarins isolated therefrom for preventing or treating Avian influenza, Swine influenza or Corona virus | |
KR102131043B1 (en) | Composition for preventing or suppressing infection of influenza virus comprising Ginseng berry polysaccharide | |
CN111588732A (en) | Application of fucoidin in resisting novel coronavirus | |
KR20120118707A (en) | A composition comprising the extract of galla rhois or the compounds isolated therefrom showing inhibiting activity of novel influenza, avian influenza, or sars syndrome | |
RU2505306C2 (en) | Composition for preventing and treating viral infections | |
AlShuwayeb et al. | Molecular and chemical therapeutic features of Urtica species | |
Zhang et al. | Potential of green tea EGCG in neutralizing SARS-CoV-2 Omicron variant with greater tropism toward the upper respiratory tract | |
Umeoguaju et al. | Plant-derived food grade substances (PDFGS) active against respiratory viruses: A systematic review of non-clinical studies | |
KR101501876B1 (en) | Composition for preventing or treating influenza virus infection comprising xylitol | |
US20240165187A1 (en) | Antiviral olive extract compositions and methods | |
EP4258874A1 (en) | Antiviral olive extract compositions and methods | |
US11980632B2 (en) | Antiviral composition containing fucosyllactose as active ingredient | |
Yu et al. | Identification of desoxyrhapontigenin as a novel antiviral agent against congenital Zika virus infection | |
US20230241144A1 (en) | Antiviral agent for preventing or treating covid-19 | |
Itharat et al. | Potential Thai herbal medicine for COVID-19 | |
Musayeva et al. | Prospects for the development of drugs with antiviral activity based on licorice | |
CN105434631A (en) | Application of zanthoxylum oil in preparing drugs or health-care products for preventing and/or treating virus flu | |
JP5173813B2 (en) | Drugs for the prevention and treatment of influenza | |
RU2780346C1 (en) | Therapeutic agent against coronavirus including an elaeocarpus sylvestris extract | |
KR102665503B1 (en) | Composition for the prevention or treatment of SARS-CoV-2 infection, comprising the extract of Galla rhois as an active ingredient | |
Downs et al. | Primary factors that determine the severity of various infections and effective nutraceutical intervention strategies | |
JP2005272355A (en) | Agent for ameliorating cerebral function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230710 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |